US20020082513A1 - Anesthesia monitoring system based on electroencephalographic signals - Google Patents

Anesthesia monitoring system based on electroencephalographic signals Download PDF

Info

Publication number
US20020082513A1
US20020082513A1 US10/007,849 US784901A US2002082513A1 US 20020082513 A1 US20020082513 A1 US 20020082513A1 US 784901 A US784901 A US 784901A US 2002082513 A1 US2002082513 A1 US 2002082513A1
Authority
US
United States
Prior art keywords
patient
index
psi
artifact
observer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/007,849
Inventor
David Ennen
Jorge Jimenez
Dominic Marro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospira Sedation Inc
Original Assignee
Physiometrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Physiometrix Inc filed Critical Physiometrix Inc
Priority to US10/007,849 priority Critical patent/US20020082513A1/en
Publication of US20020082513A1 publication Critical patent/US20020082513A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4821Determining level or depth of anaesthesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/24Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316Modalities, i.e. specific diagnostic methods
    • A61B5/369Electroencephalography [EEG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/24Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316Modalities, i.e. specific diagnostic methods
    • A61B5/369Electroencephalography [EEG]
    • A61B5/372Analysis of electroencephalograms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7203Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235Details of waveform analysis
    • A61B5/7264Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235Details of waveform analysis
    • A61B5/7253Details of waveform analysis characterised by using transforms
    • A61B5/7257Details of waveform analysis characterised by using transforms using Fourier transforms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/01Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes specially adapted for anaesthetising
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/08Other bio-electrical signals
    • A61M2230/10Electroencephalographic signals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/60Muscle strain, i.e. measured on the user
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Definitions

  • the current invention relates to the field of medical anesthesia. More particularly it relates to the field of electronic monitoring of patients undergoing anesthesia, especially for use during and after surgical operations.
  • the invention relates more specifically to the use of electroencephalograph (EEG) signals for electronically monitoring a patient's state of awareness.
  • EEG electroencephalograph
  • Anesthesiology is a medical art practiced in the United States by and large by board certified physicians (anesthesiologists) and nurses (nurse anesthetists) specifically trained to administer anesthetic drugs and monitor patients under anesthesia.
  • the state of patient anesthesia is attained by the controlled administration of various drugs with known anesthetic properties. These drugs cause the patient to lose consciousness, sensation, and motor control.
  • the physician monitors the patient's state of awareness by means of a number of disparate clinical signs known empirically to provide useful and reliable information about the patient's state of unconsciousness.
  • the patient is anesthetized prior to surgery by the specialized medical practitioner (anesthesiologist or nurse anesthetist), who administers one or more vapors or gases by inhalation or introduces anesthetic drugs intravenously.
  • Volatile substances include nitrous oxide, sevoflurane, desflurane, flurane and isoflurane, and halothane.
  • Intravenous anesthetics include pentothal, evipal, procaine, nitrous narcotic with propofol induction, methohexital, and etomidate.
  • the anesthetic should further disable the patient's motor control so that the patient cannot move. Otherwise, the patient may exhibit involuntary (reflex) muscle movements, which can disturb the area being surgically manipulated. Prevention of movement can be accomplished by anesthetic agents acting on the central nervous system or with a blockade of the neuromuscular junction with muscle relaxants.
  • the anesthesia must avoid depressing the patient's blood pressure so much as to reduce blood flow to the brain to a dangerous extent.
  • 50 mm Hg for mean arterial pressure is a lower limit.
  • a trained anesthesiologist or nurse anesthetist will monitor the patient's vital signs such as respiration and pulse rates, check the patient's pupil dilation, and check certain reflexes, such as the lash reflex, and other physiological signs to estimate the depth of anesthesia.
  • the practitioner does not have access to all of the required clinical information or other circumstances intervene.
  • the patient is draped in such a way as to make observation of some clinical indicators difficult or impossible.
  • the attention of even the best practitioner can flag.
  • a number of inventors have developed systems for using EEG signals, generally in combination with other signals, to monitor anesthesia, sleep, or other states on the consciousness-unconsciousness continuum.
  • Kaplan et al. U.S. Pat. No. 5,813,993, issued Sep. 29, 1998, disclosed a drowsiness detection system based on EEG signals. This invention relies heavily on frequencies in EEG signals above 30 Hz. It does not use any form of norming and in addition applies an ad hoc weighted sum of inverted spectral power coefficients. Maynard, U.S. Pat. No. 5,816,247, issued Oct.
  • Kangas et al. U.S. Pat. No. 5,775,330, issued Jul. 7, 1998, uses transform processing and neural net analysis to classify states of anesthesia.
  • the output of the neural net could be used to produce a single index of awareness.
  • all of these prior art systems either represent an unnecessary level of complexity or an absence of empirical basis or both.
  • This system combines certain features of EEG signals and other features including those of evoked potentials to arrive at an estimate of the patient's state of consciousness. It specifically incorporates the use of electrocardiograph (EKG) and electromyograph (EMG) electrodes and also input from a blood pressure detector and from a respiration monitor.
  • EKG electrocardiograph
  • EMG electromyograph
  • This prior art system also requires evoked potentials, specifically Brainstem Auditory Evoked Response (BAER) and Brainstem Somatosensory Evoked Response (BSER).
  • BAER Brainstem Auditory Evoked Response
  • BSER Brainstem Somatosensory Evoked Response
  • Use of evoked potentials involves the use of additional disposables and a longer set-up time. Further, this system relies very heavily on self-norming and in particular on updating
  • Prichep U.S. Pat. No. 5,083,571, issued Jan. 28, 1992, disclosed a significant advance in the utilization of EEG signals for diagnostic purposes.
  • Prichep disclosed the use of discriminant analysis to sharpen the diagnostic capability of quantities derived from EEG signals with respect to certain well-known diagnostic categories of psychiatric illness. This work compared quantities derived from a patient with parameters derived from populations of persons thought to suffer from specific identified illnesses.
  • the current invention comprises a system for using EEG signals to monitor the state of anesthesia of a patient at various stages preparatory to, during, and after administration of anesthetic and surgical operation, and in intensive care during recovery from the operation and anesthesia.
  • the system comprises a headset attached to a patient, a patient module connected to the headset, apparatus for transmitting EEG signals to an analysis unit, and the analysis unit itself.
  • the analysis unit further comprises a number of subsystems, but its essence is the Algorithm which processes the EEG signals into a parameter usable to estimate and/or track the patient's state of unconsciousness or consciousness while under anesthesia.
  • the primary function of the analysis unit is to classify anesthetized patients according to their conscious state, as determined from an analysis of volunteer data using the OAA/S scale.
  • the version of this scale used in this invention is: Modified Observer's Assessment of Alertness/Sedation Scale Response Score Responds readily to name spoken in a normal tone 5 Lethargic response to name spoken in a normal tone 4 Responds only after name is called loudly and/or repeatedly 3 Responds only after mild shaking or prodding 2 Responds only to noxious stimulus and not to mild shaking or 1 prodding Does not respond to noxious stimulus 0 Burst Suppression ⁇ 1
  • the design of the analysis unit is based on the Multiple Observer Derived Measurement Model depicted in FIG. 1.
  • An observer is a thread of execution and logic, an algorithm, which processes a stream of data and generates a measure of a characteristic(s) identified within the data stream. The principle is that is easier to construct individual observers tuned to specific characteristics in the data stream, than to create one observer that is tuned to classify an ensemble of characteristics in the data stream.
  • Observers 3 are classifier functions that detect signatures within the information. These signatures may be in the time domain, frequency domain, or a combination of the two domains. By tuning observers to specific signatures, selective filtering can be employed to improve the accuracy and latency of an observer. What may be noise to one observer may be critical information to another. This selective filtering increases the overall utilization of the acquired physiological information and thereby improving the performance of the final derived measure.
  • An Observer Mediator 4 is responsible for logically combining these individual observations in to the single Derived Parameter.
  • the Observer Mediator can weigh the individual observations by monitoring each observer's input signal quality and the context of the observation based on the patient state. The patient state is derived from the behavior of the derived parameter over time and this is fed back to the Observer Mediator. Functionally, either on demand or on a periodic basis, the Observer Mediator polls the Observers and based on patient state and the ‘quality’ of the individual observations, combines the observations into a single derived measure.
  • the Derived Parameter may be enhanced in sensitivity or scope by either further tuning of established Observers or adding additional Observers.
  • the primary output of the PSA 4000 algorithm is a single derived parameter called the Patient State Index (PSI) that maps to the OAA/S scale independent of anesthetic agent.
  • PSI Patient State Index
  • FIG. 2 The implementation of the Multiple Observer Model for this measure of state of consciousness, the PSI, is shown in FIG. 2.
  • EEG electroencephalograph
  • These raw EEG signals are filtered and decimated to reduce external noise and to satisfy data sampling rate (Nyquist) requirements.
  • the processing analyzes information in the 0.5 Hz to 50 Hz frequency range.
  • the sample data streams are divided into two primary streams: the FP1 channel is separately processed by the Beta5 Observer, all channels [FP1, FPz′, Pz, Cz] are processed by an ensemble of signal morphological classifiers 13 (artifact detectors).
  • the Beta5 Observer's signal quality can be assessed.
  • the FP1's signal quality is combined with Beta5 analysis 9 and evaluation 11 by the Beta5 Observer and propagated to the Observation Mediator.
  • the outputs of the Signal Morphology Classifiers are four artifact free EEG data streams and a declaration of the types of artifacts detected.
  • the Eyeblink Observer 19 is notified of the number and types of eyeblinks detected in the four EEG channels.
  • the Suppression Observer 20 is notified whether EEG suppression has been detected over the last time period.
  • the artifact free EEG data is further processed by the PSI Discriminant Observer 18 , which performs a more complex multiple component analysis that serves as the foundation of the consciousness algorithm.
  • the four observations: Beta5, PSI Discriminant, Eyeblink and Suppression) are propagated to the Observation Mediator 25 .
  • the Mediator combines these observations with measures of signal quality and appropriateness of observations based on patient state into an update of the Patient State Index and the associated trend.
  • the time course of the PSI is monitored and logic is applied to assess the patient's state and this information is fed back to the Observation Mediator. It is through the use of this Multiple Observer Model that a clinically functional measure of state of consciousness is realized.
  • the output of the Algorithm is a set of four processed parameters calculated every 2.5 seconds (each 2.5 second block is referred to as an epoch). These are the main output parameter, i.e., the Patient State Index (PSI); the Suppression Ratio (SR); the EMG index (EMG); and the Artifact Index (ART).
  • PSI Patient State Index
  • SR Suppression Ratio
  • EMG EMG index
  • ART Artifact Index
  • the measures in addition to the PSI provide additional information to the instrument operator on either specific aspects of the patient state or data quality. These measures are shown in FIG. 2 to be directed to the User Interface.
  • the Artifact Index is a measure of signal quality.
  • the SR-Ratio is the percentage of time in the last minute the patient's EEG has been suppressed.
  • the Beta2 component measure is related to the degree of muscle activity (EMG) detected.
  • EMG muscle activity
  • the outputs of this multiple observer based PSA 4000 algorithm is a periodic update of: the Patient State Index (the primary derived parameter), the Artifact Index, the Suppression Ratio and a measure of EMG activity.
  • the Patient State Index 164 the primary indicator of patient level of awareness, is developed to characterize the relative state of consciousness of an anesthetized patient.
  • the Algorithm outputs a periodic update of this primary parameter.
  • the Algorithm provides for upper and lower thresholds of this parameter within which the patient will be said to be in an appropriate level of unconsciousness for surgery. (Other levels may be appropriate for other conditions such as intensive care sedation.)
  • the PSI range is defined to be from 0 to 100, with higher values indicating a higher level of consciousness or awareness.
  • the Suppression Ratio 162 is an indicator of the relative amount of time that the patient's EEG waveforms exhibit a characteristic Burst Suppression pattern.
  • the Burst Suppression pattern is accepted to be an indicator of deep levels of unconsciousness under sedation. In certain situations of traumatic head injury, for example, it is necessary to reduce the brain's need for oxygen by putting the patient into a drug induced (barbiturate) coma. This brain state is observed in the EEG as Burst Suppression. For most surgical procedures, burst suppression is considered an inappropriately deep level of sedation where the anesthesiologist would normally reduce drug flow rates accordingly.
  • the Suppression Ratio is the percentage of epochs (2.5-second epochs) in the last one minute that have been declared as Suppressed Epochs.
  • the EMG Index 163 is an indicator of muscle activity. Under certain conditions, an EMG response may be interpreted as an indicator of the patient's response to pain or stress.
  • the anesthesiologist's action would depend upon the conditions present when the EMG response occurs, as EMG is a normal indication at the end of surgery. During surgery, the anesthesiologist titrates additional hypnotic for stress or analgesic for pain accordingly.
  • the EMG Index is a weighted percentage of half-epochs (over the past one minute) in which muscle activity, as measured by the power in the BETA-2 band, exceeds a threshold level. Newer epochs are weighted more heavily than the older ones.
  • the Artifact Index 165 is an indicator of data quality, or of the amount of artifacts present in the data. It is also a weighted percentage (over the past one minute). Increase in the artifact index is normal during any patient movement and may be associated with the use of certain equipment such as BOVI or train-of-four when applied to the face. Poor contact impedance aggravates all sources of artifact and will require intervention by the anesthesiologist to correct poor electrode contact with the patient.
  • FIG. 1 portrays the basic structure of the Multiple Observer Model.
  • FIG. 2 is a more detailed illustration of the Multiple Observer Model.
  • FIG. 3 shows the basic structure of the system
  • FIG. 4 shows the basic logical flow of the Algorithm.
  • FIG. 5 continues and supplements the logical flow diagram of the Algorithm.
  • FIG. 6 shows the final stages of the logical flow of the Algorithm.
  • FIG. 7 depicts the flow of information between buffers.
  • the PSA Patient Interface consists of a Patient Module 42 , patient interface cable 43 , and a Patient Electrode Set 44 designed to provide a superior quality, programmable patient interface for EEG monitoring in the OR and ICU.
  • the Patient Module is housed in a custom molded plastic enclosure with an integral universal-mounting bracket that facilitates attachment to an IV pole, bed sheet or rail.
  • a detachable patient interface cable provides a quick connect/disconnect capability to the PSA appliance or Patient Module.
  • EEG signals from the appliance are acquired with an isolated instrumentation grade, 4-channel pre-amplifier assembly and programmable multiplexed high speed A/D converter. The signal inputs are acquired referentially with reformatting provided by the Host application if necessary.
  • Preamplifier optimization for EEG is standard, with EP and ECG optional by design.
  • the combination of optically isolated data pathways, a low leakage/high isolation power converter and amplifiers with precise gain and band-pass matching results in greater than 120 dB CMRR.
  • Calibration, Impedance Test, and Normal Operation are remotely controlled through the DSP Interface using commands generated by the Host Application.
  • a full duplex connection is provided between the Patient Module and the DSP via dual optical-isolators that comply with VDE0884 for safety with extremely low leakage.
  • the power converter is a UL Listed & Medical Grade. This extreme isolation results in negligible leakage currents and assures IEC601/UL2601 compliance with superior common mode performance.
  • the proprietary ISA bus DSP card provides a real time interactive link between the host and patient module and manages the acquisition, calibration and impedance functions of the patient module. Balanced differential drivers are used to minimize EMI associated with serial data transmission while providing the ability to extend the link to approximately 1000 feet. Filtering and decimation of the acquired data takes place in the DSP.
  • the PSA 4000 analysis unit embodies and operates by means of a complex Algorithm referred to hereafter as the PSA 4000 Algorithm.
  • the system operates in three distinct modes, sometimes referred to as states, with different characteristics.
  • the three states are labeled as follows: 1) Data Accumulation; 2) Awake Patient; and 3) Unconscious Patient.
  • Two very specific and well-defined events cause the transition of the system among these four states. These events are labeled as: 1) Sufficient Data Accumulated ; and 2) Loss of Consciousness.
  • the identification of events and the switching among the states at the occurrence of an identified event is described further below following the description of the operation of the PSA 4000 Algorithm.
  • t j The time associated with a particular sample set is denoted by t j . The time resolution of the algorithm neglects the miniscule differences between time values of electrode values in a sample.
  • S j S(j) The sample associated with a particular index j.
  • S(t j ) The sample associated with a particular time.
  • the basic operational modules of the PSA 4000 Algorithm are: EEG Data Collection, Filtering and Decimation; Artifact Detection and Signal Morphology Analysis; Eye-blink Observation; Suppression Observation; Calculation of Artifact Index; Calculation of Suppression Ratio Index; FFT Calculation; Spectral Band Decomposition; Calculation of the EMG Index; EMG Beta-5 Observation; Discriminant Observer Calculation of the Probability of Correct Classification; Observer Mediation for the PSI; and Display of the PSI, the Suppression Ratio Index, the EMG Index, and the Artifact Index.
  • the patient module (PM) 42 acquires EEG data at a sampling rate of 2500 Hz.
  • the sampling and processing are established to produce a frequency representation resolution of 0.25 Hz or better.
  • the filtered sample is stored in the buffer as shown in FIGS. 8 and 9 and refreshed every half epoch.
  • Artifact detection and analysis are performed once every sample, i.e., 250 times per second in an Artifacter Bank 103 - 108 . This analysis results in an artifact type being associated with every sample that is classified as being affected by an artifact. Artifact types are also collated on an epoch-by-epoch basis. Artifact analysis is performed only onfiltered samples. As shown in FIG. 5, after the high-pass filter, the artifact engine analyzes data on four channels for 5 kinds of artifacts:
  • artifact analysis is done on a series of sample sets (sample buffers) of varying sizes.
  • the magnitude, suppression, slew rate, and eye blink artifacts are checked on a buffer of 150 samples. These 150 samples (0.6 seconds) are older than the latest 312 of the 625 samples that have gone through the high-pass filter. Thus, they are identical with the newest 150 samples in the older half of the high-pass filter buffer.
  • the rms deviation artifact is checked on the 2000 samples (8.0 seconds) before (older than) the latest 75 of the 150 samples that were checked for the previous artifact types.
  • the magnitude of the newestfiltered sample is checked, on each of the four channels 103 . (Recall that the latest filtered sample is older than the latest sample by L1 ⁇ 2 samples.) If the magnitude of at least one of the channels exceeds a set threshold, the sample is ⁇ s ′ ⁇ ( - 1 2 ⁇ L 1 ) ⁇ > M thresh 2
  • M thresh is the magnitude threshold.
  • the magnitude threshold is different for different channels and is determined empirically.
  • the slew rate detector 107 checks for sudden changes in the magnitude of samples. The rate of change cannot be greater than 15 ⁇ V over 20 ms. To check this, the detector obtains the largest sample and the smallest sample over the ⁇ slew samples older than s′( ⁇ 1 ⁇ 2L 1 ⁇ 1 ⁇ 2L 2 ). If the difference between sample s′( ⁇ 1 ⁇ 2L 1 ⁇ 1 ⁇ 2L 2 ) and either the largest or the smallest sample is greater than 15 ⁇ V, than a slew rate artifact is declared.
  • the conditions can be expressed as: s ′ ⁇ ( - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 ) - min ⁇ ( - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 - ⁇ slew , - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 ) > L thresh 3 max ⁇ ( - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 - ⁇ slew , - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 ) - s ′ ⁇ ( - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 ) > L thresh 4
  • L thresh is threshold for the slew rate artifact, equal to 15 ⁇ V. If either one of these conditions is satisfied, a slew rate artifact is declared.
  • the conditions for eye blinks, 104 and 105 are checked only if the slew rate artifact is not detected because the slope required in a slew rate artifact is larger than the slope required for eye blinks
  • the eye blink observer is mathematically similar to the slew rate detector, however, it checks for both positive and negative slopes together, i.e., it checks for EEG humps within certain parameters.
  • the observer checks for the conditions on the rise (the first half of the eyeblinks).
  • the artifactor checks the ⁇ EBSb samples older than sample s′( ⁇ 1 ⁇ 2L 1 ⁇ 1 ⁇ 2L 2 ) and obtains the largest and smallest samples.
  • a small eye blink is declared.
  • the conditions are: max ⁇ ( - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 - ⁇ EBLb , - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 ) - s ′ ⁇ ( - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 ) > ⁇ L thresh ⁇ ⁇ ⁇ or ⁇ ⁇ AND ⁇ ⁇ or 11 s ′ ⁇ ( - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 ) - min ⁇ ( - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 , - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 + ⁇ EBLa ) > L thresh 12 max ⁇ ( - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 , - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 + ⁇ EBLa ) -
  • the suppression detector 109 looks at the sum of the squared deviations of samples over the latest filtered 600 milliseconds (150 samples, denoted by L 2 ) and over the latest filtered 20 milliseconds (5 samples, denoted by L 5 ).
  • the sum of the squared deviations is: where j 1 andj 2 are sample indices, and No(j 1 , j 2 ) is the number of samples between these indices.
  • the suppression condition is where S thresh is the threshold for the Suppression Artifact.
  • the thresholds are different for the different channels and are determined empirically.
  • the suppression Observer calculates a quantity called the persistent Suppression Ratio (pSR). It is defined as the percentage, over the past 2.5 minutes, of 2.5-second epochs in which a suppression artifact was detected.
  • pSR persistent Suppression Ratio
  • the pSR is also calculated based on 2.5-sec suppressed epoch declarations, even though 1.25-sec suppressed epoch declarations are available from the current overlapping-FFT scheme. (Recall that the connecting rule is, if one of the two 1.25-sec epochs in a 2.5-sec epoch is declared suppressed, then the 2.5-sec epoch is declared suppressed.)
  • the pSR is used later in calculating the PSI from the PCC.
  • the 2.5-second Artifact Index 106 is one of the four final output parameters communicated to the user of the PSA 4000.
  • the Artifact Index is a time-weighted percentage of 48 overlapped epochs (1.25-second epochs) in the past one minute that were declared as artifacted epochs. The newer half-epochs are weighted more heavily than the older half-epochs.
  • the Artifact Index is calculated every 1.25 seconds.
  • the Suppression Ratio (SR) 143 is also one of the four final output parameters communicated to the user of the PSA 4000.
  • the SR is defined as the percentage, over the past one minute, of 2.5-second epochs in which a suppression artifact was detected.
  • the FFT of the time series i.e., the set of 625 samples, also called an epoch
  • a Hamming Window is applied to the time series data before the calculation of every FFT (see references).
  • EEG data is sliced into 2.5-second periods, called epochs, containing 625 samples each. The Fourier Transform of an epoch of EEG data is calculated.
  • FFT calculations 126 , 128 are done using a 50% overlap scheme, i.e., FFT calculations are done every 1.25-seconds for data covering the last good 2.5-second period.
  • band definitions are used in succeeding Algorithmic calculations 146 .
  • the band definitions are given in units of Hertz (Hz).
  • Hz Hertz
  • TABLE 1 Band Name Band definition (Hz) ⁇ 1.5-3.5 ⁇ 3.5-7.5 ⁇ 7.5-12.5 ⁇ 12.5-25.0 ⁇ 2 25.0-50.0 ⁇ 5 35.0-50.0 tot 1.5-25.0
  • the band tot spans only the bands ⁇ through ⁇ .
  • the EMG Index 148 is an indicator is a time-weighted percentage of 1.25-second epochs in the past one minute that had an F 1 ⁇ 2 z-component of greater than 1.96. The newer half-epochs are weighted more heavily than the older half-epochs.
  • the F 1 ⁇ 5 raw measure 126 is the power on the F 1 channel in the ⁇ 5 band.
  • the F 1 ⁇ 5 Z-component is the logarithm of the raw measure, and the F 1 ⁇ 5 Z score is the population-normed Z-component.
  • the F 1 ⁇ 5 index is defined as a running average of the F 1 ⁇ 5 Z-scores over the past twelve overlapped-epochs, in which the newest Z-score is limited to a maximum change of six population standard deviations from the latest running average.
  • a discriminant 149 is a function of statistical variable that maximizes the separation, in the variable space, of two groups of interest. It is usually a linear combination of the statistical variables. Thus, specification of the discriminant involves both specification of the variables and their weights.
  • the Raw Measures used by the discriminant observer 18 are defined by the following table: TABLE 1 Raw Measures as a combination of electrodes and bands tot ⁇ ⁇ ⁇ ⁇ ⁇ 2 FP 1 P P FP z' F P P C z P P P z P P P P
  • P refers to monopolar power and F refers to mean frequency.
  • the raw measures are averaged over 32 overlapped-epochs.
  • the first 8 are used in calculating the PCC.
  • the 9 th is used in calculating the final EMG Index output parameter.
  • Z-components are obtained from the raw components by norming to a set of population means and standard deviations, which are obtained for each component from an experimental study of normative populations.
  • Z scores are either linear combinations of Z components, or identical to the z components.
  • the z-score set used in the PSA 4000 discriminant is: TABLE 3 Z-score set used in calculating the probability of correct classification Zscore # Definition in terms of Z-components 1 monop power (FP 1 Tot) 2 mean frequency (FP z' Tot) 3 monop power (FP z' ⁇ ) - monop power (P z ⁇ ) 4 power assymetry (FP 1 C z ⁇ 2 ) 5 relative power (P z ⁇ ) 6 monop power (FP z' ⁇ ) - monop power (C z ⁇ )
  • the z-scores are linearly combined with weights such that the linear combination will maximize the separation between the two statistical groups: a group of aware people and a group of anesthetized unaware people.
  • PCC calculated every 1.25 seconds, is a rigorously defined mathematical probability, and as such, varies between zero and one.
  • Observation mediation logic 25 mediates between the different observers and indices to produce a final set of output parameters, including the PSI.
  • the initial PSI is the starting point for observer mediation logic and is simply a linear range expansion of the PCC by a factor of 100.
  • the initial PSI 152 also referred to as the PSI, undergoes a piecewise-linear transformation 153 that re-scales it according to the following formula:
  • Eye blink information is incorporated into the PSI 154 only prior to LOC, and only if the rPSI is greater than the LOC threshold of 50.
  • An epoch is considered an eye blink epoch only if there are also no other types of artifact detected.
  • the new PSI that includes the information represented by the pSR is referred to as the nPSI.
  • the nPSI is constructed as a function of the rPSI and the pSR, denoted as nPSI(pSR,rPSI) 144 .
  • nPSI(0, rPSI) 15 17 ⁇ rPSI + nPSI bot 21
  • nPSI bot 25 - 15 2 17 ⁇ 11.7647 22
  • nPSI ( pSR ⁇ 50 ,rPSI ) 0 24
  • the PSI that incorporates possible changes due to the F 1 ⁇ 5 index is called the tPSI.
  • the tPSI is a function of EMG and the nPSI.
  • the tPSI is considered a good data point and is painted non-white, even though the underlying PSI may have been artifacted and would have otherwise been painted white.
  • the PSI is considered modified by EMG only when the change is greater than 1.
  • the third factor in the equation embodies the idea that as the nPSI gets larger, there is a smaller and smaller remaining range into which the tPSI can change. The change is limited to only part of this remaining range.
  • the maximum of this limiting part is defined by the last term which also has the functional form of f(x).
  • the maximum is itself a rising function of the FP 1 ⁇ 5 index with a midpoint at a large value of 10.25 and a relatively large transition width of 3.0. This means that for most typical values of the FP 1 ⁇ 5 index, the change is limited to a maximum value of about 80. This maximum will increase as the FP 1 ⁇ 5 index increases.
  • the EMG B5 baseline is adaptively determined as follows: The EMG B5 index over the past three minutes is stored in two windows, or buffers. The first holds the indices for the oldest two minutes (of the three minutes) and the second holds the most recent 1 minute (of the three minutes). For each of these windows, the averages and standard deviations are calculated at every update (every 1.25 seconds).
  • the adaptive baseline, L is set to the average in the first window, A 1 :
  • the baseline in the beginning of the case is set to zero (the population baseline, since the EMG B5 z-scores used have been normalized to the population baseline).
  • the EMG B5 term is continuously monitored for conditions that will allow the setting of a new baseline. This allows the adaptation of EMG B5 modifications to individual patient differences.
  • the adaptive baseline algorithm is described later in the section.
  • the conditions for declaring a Repeated PSI are distinct from the conditions for Repeated Probabilities.
  • a Repeated Probability is generated if artifacts make an FFT unavailable.
  • eye blink information can modify the oPSI′.
  • the nPSI can be calculated from repeated probabilities. If the pSR happens to change during repeated probabilities, the nPSI will vary even if the underlying probability does not.
  • EMG modifications can also be active during repeated probabilities.
  • Artifacted PSI's are distinct from Repeated PSI's.
  • the Artifacted PSI declaration is made on the 2.5-second PSI values. Repeated 1.25-second PSI's or repeated full-epoch PSI's are possible (through the rules in the previous sections).
  • a 2.5-second PSI is declared an Artifacted PSI if the 2.5 second PSI is a repeated PSI AND the Artifact Index is greater than 30.
  • the Trend PSI is the running average of four 2.5 second PSI's, whether it is an Artifacted PSI or not. In the beginning of the case, the initial value of the running average is the population value of 95 for awake patients.
  • the Trend PSI is the one of the four output parameters of the PSI 4000 Algorithm.
  • the raw measure buffer of raw measure sets does has less than 24 overlapped-epochs of raw measure sets stored. EEG data acquisition is being performed, artifact analysis is being done, and FFT calculations are being made on good data. Each calculated raw measure set is added to the raw measure buffer. The following are NOT calculated: raw components, Z components, the PCC, and the PSI, and the EMG Index. The SR and the Artifact Index are calculated during this period.
  • the raw measure buffer has 24 or more (up to 32) overlapped-epochs of raw measure sets stored. EEG data acquisition is being performed, artifact analysis is being done, and FFT calculations are being made on good data. If the raw measure buffer has 32 raw measure sets, the oldest raw measure set is thrown away before the most recently calculated measure set is added. During this mode, all four output parameters are calculated from non-artifacted data. The most notable feature of this mode is the incorporation of eye blink information from artifact analysis into the PSI.
  • the Algorithm determines that sufficient data has been accumulated after the raw measure buffer has accumulated 24 overlapped-epochs of raw measure sets calculated from FFT data.
  • FFT data can only be calculated from non-artifacted epochs. Thus the time spent in this state is variable, depending on the amount of artifacts present in the data.

Abstract

A system which classifies patients according to their level of awareness or consciousness using measures derived solely from electroencephalograph (EEG) signals. The system comprises multiple observes of characteristics of signals, including artifact detectors, especially magnitude artifact detectors, eye blink detectors, stationarity/RMS detectors, slew rate detectors, and burst suppression detectors, and determination of power in certain frequency bands. The system produces a single derived probabilistic measure of conscious awareness called the patient state index (PSI) and displays values of trends in that index and values of an artifact index, an EMG index, and a suppression ratio in order to give the operator current information on the quality of the signal input. The PSI is derived from a statistical analysis using empirically derived population norms and other parameters.

Description

  • This application is a continuation application of U.S. Ser. No. 09/431, 632, filed Nov. 2, 1999, now U.S. Pat. No. 6,317,627.[0001]
  • FIELD OF THE INVENTION
  • The current invention relates to the field of medical anesthesia. More particularly it relates to the field of electronic monitoring of patients undergoing anesthesia, especially for use during and after surgical operations. The invention relates more specifically to the use of electroencephalograph (EEG) signals for electronically monitoring a patient's state of awareness. [0002]
  • BACKGROUND OF THE INVENTION
  • In current medical practice, at least for highly invasive surgery, a patient is placed under general anesthesia. Anesthesiology is a medical art practiced in the United States by and large by board certified physicians (anesthesiologists) and nurses (nurse anesthetists) specifically trained to administer anesthetic drugs and monitor patients under anesthesia. The state of patient anesthesia is attained by the controlled administration of various drugs with known anesthetic properties. These drugs cause the patient to lose consciousness, sensation, and motor control. The physician monitors the patient's state of awareness by means of a number of disparate clinical signs known empirically to provide useful and reliable information about the patient's state of unconsciousness. [0003]
  • Generally, the patient is anesthetized prior to surgery by the specialized medical practitioner (anesthesiologist or nurse anesthetist), who administers one or more vapors or gases by inhalation or introduces anesthetic drugs intravenously. Volatile substances include nitrous oxide, sevoflurane, desflurane, flurane and isoflurane, and halothane. Intravenous anesthetics include pentothal, evipal, procaine, nitrous narcotic with propofol induction, methohexital, and etomidate. [0004]
  • A correctly administered general anesthetic should remove any sensation of pain and any awareness of the operation itself. (Patients insufficiently deeply anesthetized have reported terror at becoming aware of the surgical procedure while paralyzed.) [0005]
  • The anesthetic should further disable the patient's motor control so that the patient cannot move. Otherwise, the patient may exhibit involuntary (reflex) muscle movements, which can disturb the area being surgically manipulated. Prevention of movement can be accomplished by anesthetic agents acting on the central nervous system or with a blockade of the neuromuscular junction with muscle relaxants. [0006]
  • Finally, the anesthesia must avoid depressing the patient's blood pressure so much as to reduce blood flow to the brain to a dangerous extent. Generally 50 mm Hg for mean arterial pressure is a lower limit. [0007]
  • A trained anesthesiologist or nurse anesthetist will monitor the patient's vital signs such as respiration and pulse rates, check the patient's pupil dilation, and check certain reflexes, such as the lash reflex, and other physiological signs to estimate the depth of anesthesia. In some instances, however, either the practitioner does not have access to all of the required clinical information or other circumstances intervene. For example, in some procedures the patient is draped in such a way as to make observation of some clinical indicators difficult or impossible. In addition, in very lengthy procedures the attention of even the best practitioner can flag. [0008]
  • In such circumstances it would frequently be useful to have an electronic monitor to track the patient's level of consciousness. In particular, it sometimes would be useful to have an instrument, which, once the plane of anesthesia is established qualitatively by the anesthesiologist using traditional clinical indicators, would indicate significant changes in the patient's state of anesthesia or patient responses to stimuli, which would indicate insufficient anesthesia. [0009]
  • A number of inventors have developed systems for using EEG signals, generally in combination with other signals, to monitor anesthesia, sleep, or other states on the consciousness-unconsciousness continuum. Kaplan et al., U.S. Pat. No. 5,813,993, issued Sep. 29, 1998, disclosed a drowsiness detection system based on EEG signals. This invention relies heavily on frequencies in EEG signals above 30 Hz. It does not use any form of norming and in addition applies an ad hoc weighted sum of inverted spectral power coefficients. Maynard, U.S. Pat. No. 5,816,247, issued Oct. 6, 1998, uses a combination of time domain amplitude envelope analysis and frequency analysis in conjunction with a trainable neural network to classify awareness and sleep states. Kangas et al., U.S. Pat. No. 5,775,330, issued Jul. 7, 1998, uses transform processing and neural net analysis to classify states of anesthesia. The output of the neural net could be used to produce a single index of awareness. However, all of these prior art systems either represent an unnecessary level of complexity or an absence of empirical basis or both. [0010]
  • A prior patent to John, U.S. Pat. No. 5,699,808, issued Dec. 23, 1997, discloses a system to monitor multiple patients simultaneously in the surgical recovery room or in intensive care. This system, however, combines certain features of EEG signals and other features including those of evoked potentials to arrive at an estimate of the patient's state of consciousness. It specifically incorporates the use of electrocardiograph (EKG) and electromyograph (EMG) electrodes and also input from a blood pressure detector and from a respiration monitor. This prior art system also requires evoked potentials, specifically Brainstem Auditory Evoked Response (BAER) and Brainstem Somatosensory Evoked Response (BSER). Use of evoked potentials, however, involves the use of additional disposables and a longer set-up time. Further, this system relies very heavily on self-norming and in particular on updating self-norming depending on the state of the patient. [0011]
  • An earlier patent to the same inventor, John, U.S. Pat. No. 4,557,270, issued Dec. 10, 1985, suffered from additional and more severe limitations since it required measurement of blood temperatures and volumes. Finally, John, U.S. Pat. No. 4,545,388, issued Oct. 8, 1985, disclosed the basic process of self-norming of processed EEG data. [0012]
  • Another inventor, Prichep, U.S. Pat. No. 5,083,571, issued Jan. 28, 1992, disclosed a significant advance in the utilization of EEG signals for diagnostic purposes. Prichep disclosed the use of discriminant analysis to sharpen the diagnostic capability of quantities derived from EEG signals with respect to certain well-known diagnostic categories of psychiatric illness. This work compared quantities derived from a patient with parameters derived from populations of persons thought to suffer from specific identified illnesses. [0013]
  • Finally, a prior application which has not yet issued, John, U.S. patent application Ser. No. 09/217,010, filed Dec. 21, 1998, applied discriminant analysis to the statistical differentiation of unconscious from conscious states from EEG signals. However, this invention relied heavily on BAER and BSER signals and self-norming. In addition, this invention stated, with respect to Chamoun, U.S. Pat. No. 5,010,891, issued Apr. 30, 1991, that “the comparison of patients with a normal group, in itself, is not believed to provide reliable information in the surgical context of determining if a patient will be sufficiently anesthetized.” App. at p. 4. Since that time, however, the current inventors have learned from further investigation and experimentation that population-norming is sufficiently reliable and self-norming adds unnecessarily to the complexity of the system without adding to performance. What is therefore most lacking in all of these prior art inventions is simplicity and cost effectiveness. [0014]
  • It is therefore an object of the current invention to provide an EEG based anesthesia monitoring system that completely avoids use of transducers for and inputs from other than EEG signals, that is, avoids the use of pulse, blood pressure, and respiration rate sensors and leads. It is a further object of this invention to provide an anesthesia monitoring system based on EEG signals, which completely avoids the need for BAER and BSER stimulation and response monitoring. It is a further object of this invention to provide an EEG based anesthesia monitoring system which dispenses with the cumbersome and error prone process of self-norming. It is another object of this invention to provide an EEG based anesthesia monitoring system which utilizes sample population-norming. [0015]
  • SUMMARY OF THE INVENTION
  • The current invention comprises a system for using EEG signals to monitor the state of anesthesia of a patient at various stages preparatory to, during, and after administration of anesthetic and surgical operation, and in intensive care during recovery from the operation and anesthesia. The system comprises a headset attached to a patient, a patient module connected to the headset, apparatus for transmitting EEG signals to an analysis unit, and the analysis unit itself. The analysis unit further comprises a number of subsystems, but its essence is the Algorithm which processes the EEG signals into a parameter usable to estimate and/or track the patient's state of unconsciousness or consciousness while under anesthesia. [0016]
  • The primary function of the analysis unit is to classify anesthetized patients according to their conscious state, as determined from an analysis of volunteer data using the OAA/S scale. The version of this scale used in this invention is: [0017]
    Modified Observer's Assessment of Alertness/Sedation Scale
    Response Score
    Responds readily to name spoken in a normal tone 5
    Lethargic response to name spoken in a normal tone 4
    Responds only after name is called loudly and/or repeatedly 3
    Responds only after mild shaking or prodding 2
    Responds only to noxious stimulus and not to mild shaking or 1
    prodding
    Does not respond to noxious stimulus 0
    Burst Suppression −1 
  • The design of the analysis unit is based on the Multiple Observer Derived Measurement Model depicted in FIG. 1. An observer is a thread of execution and logic, an algorithm, which processes a stream of data and generates a measure of a characteristic(s) identified within the data stream. The principle is that is easier to construct individual observers tuned to specific characteristics in the data stream, than to create one observer that is tuned to classify an ensemble of characteristics in the data stream. [0018] Observers 3 are classifier functions that detect signatures within the information. These signatures may be in the time domain, frequency domain, or a combination of the two domains. By tuning observers to specific signatures, selective filtering can be employed to improve the accuracy and latency of an observer. What may be noise to one observer may be critical information to another. This selective filtering increases the overall utilization of the acquired physiological information and thereby improving the performance of the final derived measure.
  • An [0019] Observer Mediator 4 is responsible for logically combining these individual observations in to the single Derived Parameter. The Observer Mediator can weigh the individual observations by monitoring each observer's input signal quality and the context of the observation based on the patient state. The patient state is derived from the behavior of the derived parameter over time and this is fed back to the Observer Mediator. Functionally, either on demand or on a periodic basis, the Observer Mediator polls the Observers and based on patient state and the ‘quality’ of the individual observations, combines the observations into a single derived measure. The Derived Parameter may be enhanced in sensitivity or scope by either further tuning of established Observers or adding additional Observers.
  • The primary output of the PSA 4000 algorithm is a single derived parameter called the Patient State Index (PSI) that maps to the OAA/S scale independent of anesthetic agent. The implementation of the Multiple Observer Model for this measure of state of consciousness, the PSI, is shown in FIG. 2. In this system, electroencephalograph (EEG) signals are acquired from an array of electrodes on the patient's scalp. These raw EEG signals are filtered and decimated to reduce external noise and to satisfy data sampling rate (Nyquist) requirements. [0020]
  • Following decimation, artifact analysis takes place. The EEG data is analyzed for validity and contamination. This step results in the setting of various artifact codes. After artifact analysis, the Eye-blink Observer and the Suppression Observer operate. This is followed by the calculation of the Artifact Index and the Suppression Ratio Index. For the FFT calculations, The Fast Fourier Transform (FFT) of the EEG data is calculated for each of the four channels. At this point, the system decomposes the Frequency Spectrum. In this operation the FFT spectral data is divided into frequency bands. After this, the EMG Index is calculated, and the EMG Beta-5 observer operates. The Discriminant Observer then makes its calculations, resulting in a Probability of Correct Classification based on parameters derived from sample populations. Finally, the Observer mediator combines the probability with other the output of the other three observers to the Patient State Index (PSI). [0021]
  • The processing analyzes information in the 0.5 Hz to 50 Hz frequency range. As shown in FIG. 2, the sample data streams are divided into two primary streams: the FP1 channel is separately processed by the Beta5 Observer, all channels [FP1, FPz′, Pz, Cz] are processed by an ensemble of signal morphological classifiers [0022] 13 (artifact detectors). By continuously monitoring the impedance of the FP1 electrode 10 the Beta5 Observer's signal quality can be assessed. The FP1's signal quality is combined with Beta5 analysis 9 and evaluation 11 by the Beta5 Observer and propagated to the Observation Mediator. The outputs of the Signal Morphology Classifiers are four artifact free EEG data streams and a declaration of the types of artifacts detected. Two of the artifact classifiers propagate information to Observers. The Eyeblink Observer 19 is notified of the number and types of eyeblinks detected in the four EEG channels. The Suppression Observer 20 is notified whether EEG suppression has been detected over the last time period. The artifact free EEG data is further processed by the PSI Discriminant Observer 18, which performs a more complex multiple component analysis that serves as the foundation of the consciousness algorithm. The four observations: Beta5, PSI Discriminant, Eyeblink and Suppression) are propagated to the Observation Mediator 25. The Mediator combines these observations with measures of signal quality and appropriateness of observations based on patient state into an update of the Patient State Index and the associated trend. The time course of the PSI is monitored and logic is applied to assess the patient's state and this information is fed back to the Observation Mediator. It is through the use of this Multiple Observer Model that a clinically functional measure of state of consciousness is realized.
  • The output of the Algorithm is a set of four processed parameters calculated every 2.5 seconds (each 2.5 second block is referred to as an epoch). These are the main output parameter, i.e., the Patient State Index (PSI); the Suppression Ratio (SR); the EMG index (EMG); and the Artifact Index (ART). The measures in addition to the PSI provide additional information to the instrument operator on either specific aspects of the patient state or data quality. These measures are shown in FIG. 2 to be directed to the User Interface. The Artifact Index is a measure of signal quality. The SR-Ratio is the percentage of time in the last minute the patient's EEG has been suppressed. The Beta2 component measure is related to the degree of muscle activity (EMG) detected. The outputs of this multiple observer based PSA 4000 algorithm is a periodic update of: the Patient State Index (the primary derived parameter), the Artifact Index, the Suppression Ratio and a measure of EMG activity. [0023]
  • The [0024] Patient State Index 164, the primary indicator of patient level of awareness, is developed to characterize the relative state of consciousness of an anesthetized patient. The Algorithm outputs a periodic update of this primary parameter. The Algorithm provides for upper and lower thresholds of this parameter within which the patient will be said to be in an appropriate level of unconsciousness for surgery. (Other levels may be appropriate for other conditions such as intensive care sedation.) The PSI range is defined to be from 0 to 100, with higher values indicating a higher level of consciousness or awareness.
  • The [0025] Suppression Ratio 162 is an indicator of the relative amount of time that the patient's EEG waveforms exhibit a characteristic Burst Suppression pattern. The Burst Suppression pattern is accepted to be an indicator of deep levels of unconsciousness under sedation. In certain situations of traumatic head injury, for example, it is necessary to reduce the brain's need for oxygen by putting the patient into a drug induced (barbiturate) coma. This brain state is observed in the EEG as Burst Suppression. For most surgical procedures, burst suppression is considered an inappropriately deep level of sedation where the anesthesiologist would normally reduce drug flow rates accordingly. The Suppression Ratio is the percentage of epochs (2.5-second epochs) in the last one minute that have been declared as Suppressed Epochs.
  • The [0026] EMG Index 163 is an indicator of muscle activity. Under certain conditions, an EMG response may be interpreted as an indicator of the patient's response to pain or stress.
  • The anesthesiologist's action would depend upon the conditions present when the EMG response occurs, as EMG is a normal indication at the end of surgery. During surgery, the anesthesiologist titrates additional hypnotic for stress or analgesic for pain accordingly. The EMG Index is a weighted percentage of half-epochs (over the past one minute) in which muscle activity, as measured by the power in the BETA-2 band, exceeds a threshold level. Newer epochs are weighted more heavily than the older ones. [0027]
  • The [0028] Artifact Index 165 is an indicator of data quality, or of the amount of artifacts present in the data. It is also a weighted percentage (over the past one minute). Increase in the artifact index is normal during any patient movement and may be associated with the use of certain equipment such as BOVI or train-of-four when applied to the face. Poor contact impedance aggravates all sources of artifact and will require intervention by the anesthesiologist to correct poor electrode contact with the patient.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 portrays the basic structure of the Multiple Observer Model. [0029]
  • FIG. 2 is a more detailed illustration of the Multiple Observer Model. [0030]
  • FIG. 3 shows the basic structure of the system [0031]
  • FIG. 4 shows the basic logical flow of the Algorithm. [0032]
  • FIG. 5 continues and supplements the logical flow diagram of the Algorithm. [0033]
  • FIG. 6 shows the final stages of the logical flow of the Algorithm. [0034]
  • FIG. 7 depicts the flow of information between buffers.[0035]
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT THE HEADSET AND THE PATIENT MODULE
  • In a related previous application, Ser. No. 09/113,946, filed Jul. 10, 1998, incorporated herein by reference as though fully set forth, one of the current inventors and others described a head set which can extract from the patient's head EEG signals from five favored locations of the set of international standard locations. The five favored locations are denoted in the international system by Fp1, Fp2, Fpz′, Cz, and Pz. In current embodiments these are electrically referenced to linked ear or linked mastoid contacts. EEG data from four of these five specific locations are analyzed. Alternatively, a more elaborate headset, such as that disclosed by Imran, U.S. Pat. No. 5,479,934, issued Jan. 2, 1996, can be used to obtain information from the four desired locations. [0036]
  • As shown in FIG. 3, the PSA Patient Interface consists of a [0037] Patient Module 42, patient interface cable 43, and a Patient Electrode Set 44 designed to provide a superior quality, programmable patient interface for EEG monitoring in the OR and ICU. The Patient Module is housed in a custom molded plastic enclosure with an integral universal-mounting bracket that facilitates attachment to an IV pole, bed sheet or rail. A detachable patient interface cable provides a quick connect/disconnect capability to the PSA appliance or Patient Module. EEG signals from the appliance are acquired with an isolated instrumentation grade, 4-channel pre-amplifier assembly and programmable multiplexed high speed A/D converter. The signal inputs are acquired referentially with reformatting provided by the Host application if necessary. Preamplifier optimization for EEG is standard, with EP and ECG optional by design. The combination of optically isolated data pathways, a low leakage/high isolation power converter and amplifiers with precise gain and band-pass matching results in greater than 120 dB CMRR. Calibration, Impedance Test, and Normal Operation are remotely controlled through the DSP Interface using commands generated by the Host Application. A full duplex connection is provided between the Patient Module and the DSP via dual optical-isolators that comply with VDE0884 for safety with extremely low leakage. The power converter is a UL Listed & Medical Grade. This extreme isolation results in negligible leakage currents and assures IEC601/UL2601 compliance with superior common mode performance.
  • The proprietary ISA bus DSP card provides a real time interactive link between the host and patient module and manages the acquisition, calibration and impedance functions of the patient module. Balanced differential drivers are used to minimize EMI associated with serial data transmission while providing the ability to extend the link to approximately 1000 feet. Filtering and decimation of the acquired data takes place in the DSP. [0038]
  • THE ANALYSIS UNIT
  • The PSA 4000 analysis unit embodies and operates by means of a complex Algorithm referred to hereafter as the PSA 4000 Algorithm. The system operates in three distinct modes, sometimes referred to as states, with different characteristics. The three states are labeled as follows: 1) Data Accumulation; 2) Awake Patient; and 3) Unconscious Patient. Two very specific and well-defined events cause the transition of the system among these four states. These events are labeled as: 1) Sufficient Data Accumulated ; and 2) Loss of Consciousness. The identification of events and the switching among the states at the occurrence of an identified event is described further below following the description of the operation of the PSA 4000 Algorithm. [0039]
  • The following notation is used in describing EEG data: [0040]
    A sample is actually a set of four values, one for each of the
    Sample electrode, associated with a particular instant of time.
    j All samples have a sample index, denoted by j that increases
    with time.
    j = 0 The index of the most recent sample has index 0. All other
    samples therefore have a negative index.
    tj The time associated with a particular sample set is denoted by tj.
    The time resolution of the algorithm neglects the miniscule
    differences between time values of electrode values in a sample.
    Sj, S(j) The sample associated with a particular index j.
    S(tj) The sample associated with a particular time.
  • The basic operational modules of the PSA 4000 Algorithm are: EEG Data Collection, Filtering and Decimation; Artifact Detection and Signal Morphology Analysis; Eye-blink Observation; Suppression Observation; Calculation of Artifact Index; Calculation of Suppression Ratio Index; FFT Calculation; Spectral Band Decomposition; Calculation of the EMG Index; EMG Beta-5 Observation; Discriminant Observer Calculation of the Probability of Correct Classification; Observer Mediation for the PSI; and Display of the PSI, the Suppression Ratio Index, the EMG Index, and the Artifact Index. [0041]
  • Operational Modules
  • 1) EEG Data Collection, Filtering and Decimation [0042]
  • The patient module (PM) [0043] 42 acquires EEG data at a sampling rate of 2500 Hz. The sampling and processing are established to produce a frequency representation resolution of 0.25 Hz or better.
  • Data on four channels from the headpiece are filtered and decimated by a 10-to-1 low [0044] pass decimation filter 100, as shown in FIG. 5. This is done every 10 samples resulting in 1 sample every {fraction (1/250)} sec., for an effective sampling rate of fS=250 Hz. After the 10-1 decimation and filter, the EEG data passes through a high-pass filter 102 with a cut-off frequency of fh=0.4 Hz. The most recent L1 samples are used, where L1=fS/fh=625. Filtering starts at the sample s(−½L1) i.e., samples more recent than s(−½L1) are not filtered. The average of the most recent L1′−625 samples is subtracted from sample s(−½L1). We denote the filtered s ( - 1 2 L 1 ) = s ( - 1 2 L 1 ) - 1 L 1 j = - L 1 + 1 0 s ( j ) 1
    Figure US20020082513A1-20020627-M00001
  • sample by s′(−½L[0045] 1):
  • The filtered sample is stored in the buffer as shown in FIGS. 8 and 9 and refreshed every half epoch. [0046]
  • 2) Artifact Detection and Signal Morphology Analysis [0047]
  • Artifact detection and analysis are performed once every sample, i.e., 250 times per second in an Artifacter Bank [0048] 103-108. This analysis results in an artifact type being associated with every sample that is classified as being affected by an artifact. Artifact types are also collated on an epoch-by-epoch basis. Artifact analysis is performed only onfiltered samples. As shown in FIG. 5, after the high-pass filter, the artifact engine analyzes data on four channels for 5 kinds of artifacts:
  • a. [0049] Magnitude 103
  • b. [0050] Slow Eye Blink 104
  • c. [0051] Fast Eye Blink 105
  • d. [0052] Slew rate 107
  • e. [0053] Stationarity 108.
  • These are later combined in an [0054] Artifact Index module 106.
  • As is illustrated in FIG. 7, artifact analysis is done on a series of sample sets (sample buffers) of varying sizes. The magnitude, suppression, slew rate, and eye blink artifacts are checked on a buffer of 150 samples. These 150 samples (0.6 seconds) are older than the latest 312 of the 625 samples that have gone through the high-pass filter. Thus, they are identical with the newest 150 samples in the older half of the high-pass filter buffer. Similarly, the rms deviation artifact is checked on the 2000 samples (8.0 seconds) before (older than) the latest 75 of the 150 samples that were checked for the previous artifact types. [0055]
  • The conditions used in checking for the various types of artifacts are: [0056]
  • i) Magnitude [0057]
  • The magnitude of the newestfiltered sample is checked, on each of the four [0058] channels 103. (Recall that the latest filtered sample is older than the latest sample by L½ samples.) If the magnitude of at least one of the channels exceeds a set threshold, the sample is s ( - 1 2 L 1 ) > M thresh 2
    Figure US20020082513A1-20020627-M00002
  • classified as a magnitude artifact. Thus the condition is where M[0059] thresh is the magnitude threshold. The magnitude threshold is different for different channels and is determined empirically.
  • ii) Slew Rate [0060]
  • The [0061] slew rate detector 107 checks for sudden changes in the magnitude of samples. The rate of change cannot be greater than 15 μV over 20 ms. To check this, the detector obtains the largest sample and the smallest sample over the δslew samples older than s′(−½L1−½L2). If the difference between sample s′(−½L1−½L2) and either the largest or the smallest sample is greater than 15 μV, than a slew rate artifact is declared. Mathematically, the conditions can be expressed as: s ( - 1 2 L 1 - 1 2 L 2 ) - min ( - 1 2 L 1 - 1 2 L 2 - δ slew , - 1 2 L 1 - 1 2 L 2 ) > L thresh 3
    Figure US20020082513A1-20020627-M00003
    max ( - 1 2 L 1 - 1 2 L 2 - δ slew , - 1 2 L 1 - 1 2 L 2 ) - s ( - 1 2 L 1 - 1 2 L 2 ) > L thresh 4
    Figure US20020082513A1-20020627-M00004
  • where L[0062] thresh is threshold for the slew rate artifact, equal to 15 μV. If either one of these conditions is satisfied, a slew rate artifact is declared.
  • iii) Stationarity [0063]
  • The stationarity artifact is checked [0064] 108 on the L3=2000 samples (8.0 seconds) before (older than) sample s′(−½L1−½L2) . First the sum of the squares of the samples (not the squares of the deviations) is calculated. This is compared to the sample in the middle of the 2000 samples s′(−½L1−½L2−½L3). The following condition is checked: s ( - 1 2 L 1 - 1 2 L 2 - 1 2 L 3 ) > bigger ( f scale j [ s ( j ) ] 2 , f limit ) 5
    Figure US20020082513A1-20020627-M00005
  • If this condition is satisfied for a given scale factor and limit term then a stationarity artifact is declared. [0065]
  • 3) Eyeblink Observation [0066]
  • The conditions for eye blinks, [0067] 104 and 105, are checked only if the slew rate artifact is not detected because the slope required in a slew rate artifact is larger than the slope required for eye blinks The eye blink observer is mathematically similar to the slew rate detector, however, it checks for both positive and negative slopes together, i.e., it checks for EEG humps within certain parameters.
  • First, the observer checks for the conditions on the rise (the first half of the eyeblinks). For small eye blinks, the artifactor checks the δ[0068] EBSb samples older than sample s′(−½L1−½L2) and obtains the largest and smallest samples. The following conditions are checked: s ( - 1 2 L 1 - 1 2 L 2 ) - min ( - 1 2 L 1 - 1 2 L 2 - δ EBSb , - 1 2 L 1 - 1 2 L 2 ) > L thresh 6 max ( - 1 2 L 1 - 1 2 L 2 - δ EBSb , - 1 2 L 1 - 1 2 L 2 ) - s ( - 1 2 L 1 - 1 2 L 2 ) > L thresh 7
    Figure US20020082513A1-20020627-M00006
  • If at least one of these conditions is satisfied, then the conditions on the second half of the eye blink are checked. The observer checks the δ[0069] EBSa filtered samples newer than sample s′(−½L1−½L2) and obtains the largest and smallest samples. One of the following s ( - 1 2 L 1 - 1 2 L 2 ) - min ( - 1 2 L 1 - 1 2 L 2 , - 1 2 L 1 - 1 2 L 2 + δ EBSa ) > L thresh or 8 max ( - 1 2 L 1 - 1 2 L 2 - δ EBSb , - 1 2 L 1 - 1 2 L 2 ) - s ( - 1 2 L 1 - 1 2 L 2 ) > L thresh . 9
    Figure US20020082513A1-20020627-M00007
  • conditions must be satisfied: [0070]
  • If (Equation 8 or Equation 9) AND ([0071] Equation 10 or Equation 11) is satisfied, then s ( - 1 2 L 1 - 1 2 L 2 ) - min ( - 1 2 L 1 - 1 2 L 2 - δ EBLb , - 1 2 L 1 - 1 2 L 2 ) > L thresh 10
    Figure US20020082513A1-20020627-M00008
  • a small eye blink is declared. Similarly, for large eye blinks, the conditions are: [0072] max ( - 1 2 L 1 - 1 2 L 2 - δ EBLb , - 1 2 L 1 - 1 2 L 2 ) - s ( - 1 2 L 1 - 1 2 L 2 ) > L thresh or AND or 11 s ( - 1 2 L 1 - 1 2 L 2 ) - min ( - 1 2 L 1 - 1 2 L 2 , - 1 2 L 1 - 1 2 L 2 + δ EBLa ) > L thresh 12
    Figure US20020082513A1-20020627-M00009
    max ( - 1 2 L 1 - 1 2 L 2 , - 1 2 L 1 - 1 2 L 2 + δ EBLa ) - s ( - 1 2 L 1 - 1 2 L 2 ) > L thresh 13
    Figure US20020082513A1-20020627-M00010
  • If ([0073] Equation 12 or Equation 13) AND (Equation 14 or Equation 15) is satisfied, then a large eyeblink is declared. The threshold parameters for eye blinks are determined empirically.
  • 4) Suppression Observation [0074]
  • Every time a newfiltered sample is obtained, the [0075] suppression detector 109 looks at the sum of the squared deviations of samples over the latest filtered 600 milliseconds (150 samples, denoted by L2) and over the latest filtered 20 milliseconds (5 samples, denoted by L5). Δ ( j 1 , j 2 ) = ( j = j 1 j 2 [ s ( j ) ] 2 ) - 1 N ( j 1 , j 2 ) [ j = j 1 j 2 s ( j ) ] 2 14
    Figure US20020082513A1-20020627-M00011
  • For reference, the sum of the squared deviations, generically defined, is: where j[0076] 1 andj2 are sample indices, and No(j1, j2) is the number of samples between these indices. This quantity is related to variance of the same sample set (the average of the sum of the squared σ j 1 , j 2 2 = Δ ( j 1 , j 2 ) N ( j 1 , j 2 ) 15
    Figure US20020082513A1-20020627-M00012
  • deviations) through [0077]
  • The difference between these two sums of squared deviations is intended as an approximate measure of the power in the band between 1.67 Hz and 50 Hz. If, on any one of the four channels, this power is less than a set threshold, then a suppression-type artifact is [0078] Δ ( - 1 2 L 1 - L 2 , - 1 2 L 1 ) - Δ ( - 1 2 L 1 - L 5 , - 1 2 L 1 ) < S thresh 16
    Figure US20020082513A1-20020627-M00013
  • associated with that sample. Thus the suppression condition is where S[0079] thresh is the threshold for the Suppression Artifact. The thresholds are different for the different channels and are determined empirically.
  • (a) Persistent Suppression Ratio (SR) [0080]
  • The suppression Observer calculates a quantity called the persistent Suppression Ratio (pSR). It is defined as the percentage, over the past 2.5 minutes, of 2.5-second epochs in which a suppression artifact was detected. The pSR is used later in calculating the PSI from the PCC. [0081]
  • The pSR is also calculated based on 2.5-sec suppressed epoch declarations, even though 1.25-sec suppressed epoch declarations are available from the current overlapping-FFT scheme. (Recall that the connecting rule is, if one of the two 1.25-sec epochs in a 2.5-sec epoch is declared suppressed, then the 2.5-sec epoch is declared suppressed.) The pSR is used later in calculating the PSI from the PCC. [0082]
  • 5) Calculation of Artifact Index [0083]
  • The 2.5-[0084] second Artifact Index 106 is one of the four final output parameters communicated to the user of the PSA 4000. The Artifact Index is a time-weighted percentage of 48 overlapped epochs (1.25-second epochs) in the past one minute that were declared as artifacted epochs. The newer half-epochs are weighted more heavily than the older half-epochs. The Artifact Index is calculated every 1.25 seconds.
  • 6) Calculation of Suppression Ratio Index [0085]
  • The Suppression Ratio (SR) [0086] 143 is also one of the four final output parameters communicated to the user of the PSA 4000. The SR is defined as the percentage, over the past one minute, of 2.5-second epochs in which a suppression artifact was detected.
  • 7) FFT Calculation [0087]
  • Whenever 625 continuous good (non-artifacted) samples are calculated, the FFT of the time series (i.e., the set of 625 samples, also called an epoch) is calculated. A Hamming Window is applied to the time series data before the calculation of every FFT (see references). EEG data is sliced into 2.5-second periods, called epochs, containing 625 samples each. The Fourier Transform of an epoch of EEG data is calculated. [0088]
  • [0089] FFT calculations 126, 128 are done using a 50% overlap scheme, i.e., FFT calculations are done every 1.25-seconds for data covering the last good 2.5-second period.
  • 8) Spectral Band Decomposition [0090]
  • The following band definitions are used in succeeding [0091] Algorithmic calculations 146. The band definitions are given in units of Hertz (Hz).
    TABLE 1
    Band Name Band definition (Hz)
    Δ 1.5-3.5
    θ 3.5-7.5
    α  7.5-12.5
    β 12.5-25.0
    β2 25.0-50.0
    β5 35.0-50.0
    tot  1.5-25.0
  • The band tot spans only the bands Δ through β. [0092]
  • 9) Calculation of the EMG Index [0093]
  • The [0094] EMG Index 148 is an indicator is a time-weighted percentage of 1.25-second epochs in the past one minute that had an F1β2 z-component of greater than 1.96. The newer half-epochs are weighted more heavily than the older half-epochs.
  • 10) EMG BETA-5 observation [0095]
  • The F[0096] 1β5 raw measure 126, is the power on the F1 channel in the β5 band. The F1β5 Z-component is the logarithm of the raw measure, and the F1β5 Z score is the population-normed Z-component. The F1β5 index is defined as a running average of the F1β5 Z-scores over the past twelve overlapped-epochs, in which the newest Z-score is limited to a maximum change of six population standard deviations from the latest running average.
  • 11) Discriminant observer calculations [0097]
  • A [0098] discriminant 149 is a function of statistical variable that maximizes the separation, in the variable space, of two groups of interest. It is usually a linear combination of the statistical variables. Thus, specification of the discriminant involves both specification of the variables and their weights.
  • i) Raw measures for the Discriminant Observers [0099]
  • The Raw Measures used by the [0100] discriminant observer 18 are defined by the following table:
    TABLE 1
    Raw Measures as a combination of electrodes and bands
    tot Δ θ α β β2
    FP1 P P
    FPz' F P P
    Cz P P
    Pz P P P
  • In this matrix, P refers to monopolar power and F refers to mean frequency. The raw measures are averaged over 32 overlapped-epochs. [0101]
  • ii) Components for the Discriminant Observer [0102]
  • The specific set of raw components calculated in the PSA 4000 Algorithm are as follows: [0103]
    TABLE 2
    Raw-components used in calculating the probability of
    correct classification
    Raw-Component # QUANTITY CHANNEL/BAND(S)
    1 monop abs power FP1Tot
    2 mean frequency FPz'Tot
    3 monop abs power Pzα
    4 power assymetry FP1Czβ2
    5 monop power FPz'α
    6 relative power PzΔ
    7 monop power FPz'β
    8 monop power Czβ
    9 monop abs power FP1β2
  • The first 8 are used in calculating the PCC. The 9[0104] th is used in calculating the final EMG Index output parameter. Z-components are obtained from the raw components by norming to a set of population means and standard deviations, which are obtained for each component from an experimental study of normative populations.
  • iv) Z-Scores [0105]
  • Z scores are either linear combinations of Z components, or identical to the z components. The z-score set used in the PSA 4000 discriminant is: [0106]
    TABLE 3
    Z-score set used in calculating the probability of correct classification
    Zscore # Definition in terms of Z-components
    1 monop power (FP1Tot)
    2 mean frequency (FPz'Tot)
    3 monop power (FPz'α) - monop power (Pzα)
    4 power assymetry (FP1Czβ2)
    5 relative power (PzΔ)
    6 monop power (FPz'β) - monop power (Czβ)
  • The z-scores are linearly combined with weights such that the linear combination will maximize the separation between the two statistical groups: a group of aware people and a group of anesthetized unaware people. [0107]
  • v) Calculation of the Probability of Correct Classification [0108]
  • The probability that a set of z-scores can be correctly classified as belonging to an aware group, as opposed to an anesthetized unaware group, is obtained from the discriminant by using a sleep term, [0109] S = c s + i = 1 6 w i ( S ) z i 17
    Figure US20020082513A1-20020627-M00014
  • where c[0110] s is a constant term and the w's are discriminant weights. Similarly, the wake term is W = c w + i = 1 6 w i ( W ) z i 18
    Figure US20020082513A1-20020627-M00015
  • The probability of correct classification is [0111] PCC = e W e W + e S 19
    Figure US20020082513A1-20020627-M00016
  • The PCC, calculated every 1.25 seconds, is a rigorously defined mathematical probability, and as such, varies between zero and one. [0112]
  • 12) Observer Mediation [0113]
  • [0114] Observation mediation logic 25 mediates between the different observers and indices to produce a final set of output parameters, including the PSI.
  • a) The Initial PSI [0115]
  • The initial PSI is the starting point for observer mediation logic and is simply a linear range expansion of the PCC by a factor of 100. [0116]
  • b) Variability Transformation of the initial PSI [0117]
  • The [0118] initial PSI 152, also referred to as the PSI, undergoes a piecewise-linear transformation 153 that re-scales it according to the following formula:
  • rPSI=1.7(oPSI)−70.0oPSI≧85.0
  • rPSI=0.7(oPSI)+15.0 85.0>oPSI>15.0
  • rPSI=1.7(oPSI)15.0>oPSI   20
  • The result is termed the rPSI. [0119]
  • c) Mediation of Eye Blink Information [0120]
  • Eye blink information is incorporated into the [0121] PSI 154 only prior to LOC, and only if the rPSI is greater than the LOC threshold of 50. An epoch is considered an eye blink epoch only if there are also no other types of artifact detected.
  • If an eye blink epoch is detected during an Indeterminate Probability (i.e., before an rPSI can be calculated, because the raw measure buffer is not yet full) then an rPSI of 95 is reported. This rPSI and all succeeding rPSI values (until the buffer is full enough to calculate a value) are then treated as if they originated from a calculated probability, i.e., it undergoes the transformations and calculations that lead to the PSI. After this first eye blink, whenever an eye blink is detected, the current rPSI is averaged with 99, and the result becomes the current rPSI. [0122]
  • d) Mediation of Suppression Information [0123]
  • The new PSI that includes the information represented by the pSR is referred to as the nPSI. The nPSI is constructed as a function of the rPSI and the pSR, denoted as nPSI(pSR,rPSI) [0124] 144.
  • The transformation when pSR=0, i.e., nPSI(0, rPSI), is an important special case of the whole transformation. Its result is a compression of the rPSI range (0-100) into a new scale. The new, compressed scale has a minimum value, nPSI[0125] bot, so that range of the new scale is (nPSIbot−100). The re-scaling is chosen so that a rPSI of 15 maps to a nPSI of 25. This completely determines the transformation equation, because the maxima of the two scales are the same. The transformation is given by nPSI ( 0 , rPSI ) = 15 17 rPSI + nPSI bot 21
    Figure US20020082513A1-20020627-M00017
  • where nPSI[0126] bot is given by nPSI bot = 25 - 15 2 17 11.7647 22
    Figure US20020082513A1-20020627-M00018
  • Another condition is the special case at pSR=15, i.e., nPSI(15, rPSI). We impose the condition [0127]
  • nPSI(pSR=15, rPSI≧15)=15   23
  • A third condition determining the transformation is case when pSR≧50. Then we have [0128]
  • nPSI(pSR≧50,rPSI)=0   24
  • e) Mediation of Beta5 Information [0129]
  • Incorporation of EMG information into the PSI is based on the F[0130] 1β5 index 140. This modification is a refinement of the EMG information already in the PSI by virtue of the F1β2 term. EMG modifications are possible only when the pSR=0, and only after a time threshold of 15 minutes after the declaration of Loss Of Consciousness (LOC). EMG modifications are not possible when the patient module is disconnected. In addition, there is a timeout period of ⅓ minute after the end of the PM Disconnect during which EMG modifications are not possible. When a BAD IMPEDANCE is detected, the EMG power used is the last one calculated before the BAD IMPEDANCE condition.
  • The PSI that incorporates possible changes due to the F[0131] 1β5 index is called the tPSI. (The tPSI is a function of EMG and the nPSI.)
  • When the PSI is modified by the F[0132] 1β5 index then the tPSI is considered a good data point and is painted non-white, even though the underlying PSI may have been artifacted and would have otherwise been painted white. The PSI is considered modified by EMG only when the change is greater than 1.
  • The change from nPSI to tPSI is calculated using the following equation: we express the change as the product of three functions: [0133]
  • ΔPSI=f(F1,β5)g(nPSI)h(F1,β5, nPSI)   25
  • The first function governs the rise along the F[0134] 1β5 axis: functions: f ( F1β 5 ) = ( 1 1 + e - ( F1β 5 - B m ) / B w ) 26
    Figure US20020082513A1-20020627-M00019
  • The second function governs the rise along the nPSI axis: [0135] g ( nPSI ) = ( 1 1 + e - ( nPSI - P m ) / P w ) 27
    Figure US20020082513A1-20020627-M00020
  • The third function limits the change as nPSI becomes bigger, because there is a smaller remaining range of tPSI into which to change: [0136] h ( F1β 5 , nPSI ) = t c - t c n c + 100 - n c 1 + e - ( F1β 5 - b m ) / b w nPSI 28
    Figure US20020082513A1-20020627-M00021
  • In each of the three functions there is a functional form F(x)=(1+exp((x+c)/d))[0137] −1. This function creates a rising transition from 0 to 1, with the midpoint of the transition occurring at x=c, and the width (or sharpness) of the transition determined by d.
  • Thus the first of the three equations above defines the contribution of the FP[0138] 1β5 index as rising from zero around an index of approximately 1.25, and the second factor defines that the change can only occur be significant at nPSI values starting around a value of 19.
  • The variable A in the equation above has a value of A=1.25−baseline. The baseline in the beginning of the case is set to zero (the population baseline, since the EMG B5 z-scores used have been normalized to the population baseline). However the EMG B5 term is continuously monitored for conditions that will allow the setting of a new baseline. This allows the adaptation of EMG B5 modifications to individual patient differences. The adaptive baseline algorithm is described later in this section. [0139]
  • The third factor in the equation embodies the idea that as the nPSI gets larger, there is a smaller and smaller remaining range into which the tPSI can change. The change is limited to only part of this remaining range. The maximum of this limiting part is defined by the last term which also has the functional form of f(x). The maximum is itself a rising function of the FP[0140] 1β5 index with a midpoint at a large value of 10.25 and a relatively large transition width of 3.0. This means that for most typical values of the FP1β5 index, the change is limited to a maximum value of about 80. This maximum will increase as the FP1β5 index increases.
  • The tPSI is given by [0141]
  • tPSI=nPSI+ΔPSI   29
  • The EMG B5 baseline is adaptively determined as follows: The EMG B5 index over the past three minutes is stored in two windows, or buffers. The first holds the indices for the oldest two minutes (of the three minutes) and the second holds the most recent 1 minute (of the three minutes). For each of these windows, the averages and standard deviations are calculated at every update (every 1.25 seconds). [0142]
  • Every update, the following conditions on the averages and standard deviations are checked: [0143]
  • (F1β5)1<A1  30
  • |(F 1β5)1−(F 1β5)2 |<D   31
  • σ2<S2   33
  • σ1<S1   32
  • If all four conditions are satisfied, then the adaptive baseline, L, is set to the average in the first window, A[0144] 1:
  • L=A1  34
  • The variable A in the equation above has a value of A=1.25−baseline. The baseline in the beginning of the case is set to zero (the population baseline, since the EMG B5 z-scores used have been normalized to the population baseline). However the EMG B5 term is continuously monitored for conditions that will allow the setting of a new baseline. This allows the adaptation of EMG B5 modifications to individual patient differences. The adaptive baseline algorithm is described later in the section. [0145]
  • f) Mediation of Artifact Information [0146]
  • i) Repeated PSI [0147]
  • The conditions for declaring a Repeated PSI are distinct from the conditions for Repeated Probabilities. A Repeated Probability is generated if artifacts make an FFT unavailable. However, several things can cause the PSI to vary even if the underlying probability is a repeated probability. First, eye blink information can modify the oPSI′. Secondly, the nPSI can be calculated from repeated probabilities. If the pSR happens to change during repeated probabilities, the nPSI will vary even if the underlying probability does not. Third, EMG modifications can also be active during repeated probabilities. [0148]
  • The following conditions are used in the declaration of a Repeated PSI: if an epoch is an artifacted epoch, AND the PSI has NOT been modified by either eye blinks or EMG, AND the Artifact Index is greater than 30, then the tPSI is a Repeated PSI. [0149]
  • “Repeated PSI” is merely terminology, carried over from “Repeated Probability”. It does not imply that the PSI is actually repeated, though in most cases it will be. [0150]
  • ii) Artifacted PSI [0151]
  • Artifacted PSI's are distinct from Repeated PSI's. The Artifacted PSI declaration is made on the 2.5-second PSI values. Repeated 1.25-second PSI's or repeated full-epoch PSI's are possible (through the rules in the previous sections). A 2.5-second PSI is declared an Artifacted PSI if the 2.5 second PSI is a repeated PSI AND the Artifact Index is greater than 30. [0152]
  • iii) Trend PSI [0153]
  • The Trend PSI is the running average of four 2.5 second PSI's, whether it is an Artifacted PSI or not. In the beginning of the case, the initial value of the running average is the population value of 95 for awake patients. The Trend PSI is the one of the four output parameters of the PSI 4000 Algorithm. [0154]
  • SYSTEM STATES AND SWITCHING
  • As previously noted, the system operates in four distinct modes, each operating significantly differently. The four specifically defined states are as follows. [0155]
  • 1) States [0156]
  • a) Data Accumulation [0157]
  • During Data Accumulation, the raw measure buffer of raw measure sets does has less than 24 overlapped-epochs of raw measure sets stored. EEG data acquisition is being performed, artifact analysis is being done, and FFT calculations are being made on good data. Each calculated raw measure set is added to the raw measure buffer. The following are NOT calculated: raw components, Z components, the PCC, and the PSI, and the EMG Index. The SR and the Artifact Index are calculated during this period. [0158]
  • b) Awake State [0159]
  • In Awake State, the raw measure buffer has 24 or more (up to 32) overlapped-epochs of raw measure sets stored. EEG data acquisition is being performed, artifact analysis is being done, and FFT calculations are being made on good data. If the raw measure buffer has 32 raw measure sets, the oldest raw measure set is thrown away before the most recently calculated measure set is added. During this mode, all four output parameters are calculated from non-artifacted data. The most notable feature of this mode is the incorporation of eye blink information from artifact analysis into the PSI. [0160]
  • c) Unconscious State [0161]
  • In Unconscious State, eye blink information is ignored and is NOT incorporated into the PSI. Otherwise, the operation of the Algorithm is the same as in Awake State. [0162]
  • 1) Transition Events [0163]
  • The following three transition events initiate a transition between the four states. [0164]
  • a) Sufficient Data Accumulated [0165]
  • The Algorithm determines that sufficient data has been accumulated after the raw measure buffer has accumulated 24 overlapped-epochs of raw measure sets calculated from FFT data. FFT data can only be calculated from non-artifacted epochs. Thus the time spent in this state is variable, depending on the amount of artifacts present in the data. [0166]
  • b) Loss Of Consciousness [0167]
  • If the PSI has 18 consecutive non-repeated values below 50, Loss Of Consciousness is declared. This declaration is used to disable the incorporation of eye blink information into the PSI. [0168]

Claims (3)

What is claimed is:
1. An apparatus for classifying the level of awareness of a patient using electroencephalograph (EEG) signals, comprising:
a. a plurality of patient electrodes whereby a plurality of patient EEG signals is acquired;
b. a patient module connected to the patient electrode set, said patient module having a plurality of channels corresponding to the plurality of patient electrodes; and
c. at least one analysis unit connected to the patient module, said analysis unit having a plurality of channels corresponding to the plurality of patient electrodes, and said analysis unit comprising,
i. a plurality of modules comprising observers configured to produce measures of specific characteristics in the plural EEG signals;
ii. an observer mediator which mediates among plural outputs of the plural observers according to a mediation logic, whereby the at least one observer mediator produces at least one output parameter characterizing the patient's state of anesthesia; and
wherein one of the modules comprising an observer comprises a subsystem which constructs and sends to the observer mediator a statistical discriminant based on plural statistical variables derived from power and frequency information extracted from plural EEG signals.
2. The apparatus of claim 1, wherein the plural observers in each of the plural channels are plural classifiers which detect signatures within each of the plural EEG signals.
3. The apparatus of claim 1 in which the single derived parameter is a Patient State Index.
US10/007,849 1999-11-02 2001-11-13 Anesthesia monitoring system based on electroencephalographic signals Abandoned US20020082513A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/007,849 US20020082513A1 (en) 1999-11-02 2001-11-13 Anesthesia monitoring system based on electroencephalographic signals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/431,632 US6317627B1 (en) 1999-11-02 1999-11-02 Anesthesia monitoring system based on electroencephalographic signals
US10/007,849 US20020082513A1 (en) 1999-11-02 2001-11-13 Anesthesia monitoring system based on electroencephalographic signals

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/431,632 Continuation US6317627B1 (en) 1999-11-02 1999-11-02 Anesthesia monitoring system based on electroencephalographic signals

Publications (1)

Publication Number Publication Date
US20020082513A1 true US20020082513A1 (en) 2002-06-27

Family

ID=23712775

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/431,632 Expired - Lifetime US6317627B1 (en) 1999-11-02 1999-11-02 Anesthesia monitoring system based on electroencephalographic signals
US10/007,849 Abandoned US20020082513A1 (en) 1999-11-02 2001-11-13 Anesthesia monitoring system based on electroencephalographic signals

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/431,632 Expired - Lifetime US6317627B1 (en) 1999-11-02 1999-11-02 Anesthesia monitoring system based on electroencephalographic signals

Country Status (1)

Country Link
US (2) US6317627B1 (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040225179A1 (en) * 2003-02-28 2004-11-11 Consolidated Research Of Richmond, Inc. Automated insomnia treatment system
US20040236240A1 (en) * 2000-12-07 2004-11-25 Kraus Baruch Shlomo Automated interpretive medical care system and methodology
US20040243017A1 (en) * 2003-05-06 2004-12-02 Elvir Causevic Anesthesia and sedation monitoring system and method
US20060019224A1 (en) * 2004-07-23 2006-01-26 Pics, Inc. Insomnia assessment and treatment device and method
US20070016095A1 (en) * 2005-05-10 2007-01-18 Low Philip S Automated detection of sleep and waking states
US20070071160A1 (en) * 2005-09-27 2007-03-29 Akihiko Nishide X-ray ct apparatus
WO2007059248A2 (en) * 2005-11-15 2007-05-24 Hospira, Inc System for monitoring and separating eeg and emg signals
US20070167694A1 (en) * 2005-12-21 2007-07-19 Everest Biomedical Instruments Co. Integrated Portable Anesthesia and Sedation Monitoring Apparatus
US20070185697A1 (en) * 2006-02-07 2007-08-09 Microsoft Corporation Using electroencephalograph signals for task classification and activity recognition
US20080317672A1 (en) * 2007-06-20 2008-12-25 The General Electric Company Detection of anomalies in measurement of level of hypnosis
US20100094103A1 (en) * 2003-02-28 2010-04-15 Consolidated Research Of Richmond, Inc Automated treatment system for sleep
DE102009053256A1 (en) * 2009-11-06 2011-05-19 Baars, Jan H., Dr. med. Method for determining the analgesic level of a sedated or anaesthetized individual
US20110224569A1 (en) * 2010-03-10 2011-09-15 Robert Isenhart Method and device for removing eeg artifacts
US20110295196A1 (en) * 2009-01-15 2011-12-01 Hopital Foch System for controlling means for injection of anesthetics or sedatives
CN103040459A (en) * 2013-01-05 2013-04-17 西安交通大学 Method of high-fidelity filtering for power frequency interferences in multichannel feeble physiological information recording system
CN103169466A (en) * 2013-04-01 2013-06-26 张宇奇 Algesia monitoring system and monitoring method for anesthesia
US8666484B2 (en) 2011-11-25 2014-03-04 Persyst Development Corporation Method and system for displaying EEG data
US20140081094A1 (en) * 2011-05-02 2014-03-20 Denis Jordan Method for consciousness and pain monitoring, module for analyzing eeg signals, and eeg anesthesia monitor
US8821397B2 (en) 2010-09-28 2014-09-02 Masimo Corporation Depth of consciousness monitor including oximeter
US8838198B2 (en) 2008-11-14 2014-09-16 Neuronetrix Solutions, Llc Electrode system
US9364163B2 (en) 2012-01-24 2016-06-14 Neurovigil, Inc. Correlating brain signal to intentional and unintentional changes in brain state
US9775545B2 (en) 2010-09-28 2017-10-03 Masimo Corporation Magnetic electrical connector for patient monitors
US9849241B2 (en) 2013-04-24 2017-12-26 Fresenius Kabi Deutschland Gmbh Method of operating a control device for controlling an infusion device
US10154815B2 (en) 2014-10-07 2018-12-18 Masimo Corporation Modular physiological sensors
US10537677B2 (en) 2009-01-15 2020-01-21 Medsteer System for controlling injectors of anaesthetics or sedatives with a view to inducing anaesthesia or sedation
US11273283B2 (en) 2017-12-31 2022-03-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US11452839B2 (en) 2018-09-14 2022-09-27 Neuroenhancement Lab, LLC System and method of improving sleep
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep

Families Citing this family (289)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9702434A (en) 1991-03-07 1998-05-31 Masimo Corp Signal processing apparatus.
US5638818A (en) 1991-03-21 1997-06-17 Masimo Corporation Low noise optical probe
US8019400B2 (en) 1994-10-07 2011-09-13 Masimo Corporation Signal processing apparatus
EP1905352B1 (en) 1994-10-07 2014-07-16 Masimo Corporation Signal processing method
US6002952A (en) 1997-04-14 1999-12-14 Masimo Corporation Signal processing apparatus and method
US6229856B1 (en) 1997-04-14 2001-05-08 Masimo Corporation Method and apparatus for demodulating signals in a pulse oximetry system
EP2319398B1 (en) 1998-06-03 2019-01-16 Masimo Corporation Stereo pulse oximeter
US7245953B1 (en) 1999-04-12 2007-07-17 Masimo Corporation Reusable pulse oximeter probe and disposable bandage apparatii
US6721585B1 (en) 1998-10-15 2004-04-13 Sensidyne, Inc. Universal modular pulse oximeter probe for use with reusable and disposable patient attachment devices
US6463311B1 (en) 1998-12-30 2002-10-08 Masimo Corporation Plethysmograph pulse recognition processor
US6684090B2 (en) 1999-01-07 2004-01-27 Masimo Corporation Pulse oximetry data confidence indicator
US6360114B1 (en) 1999-03-25 2002-03-19 Masimo Corporation Pulse oximeter probe-off detector
US6515273B2 (en) 1999-08-26 2003-02-04 Masimo Corporation System for indicating the expiration of the useful operating life of a pulse oximetry sensor
ATE326900T1 (en) * 1999-10-27 2006-06-15 Hospira Sedation Inc MODULE FOR OBTAINING ELECTROENCEPHALOGRAPHY SIGNALS FROM A PATIENT
US6377829B1 (en) 1999-12-09 2002-04-23 Masimo Corporation Resposable pulse oximetry sensor
DE10015026C2 (en) * 2000-03-25 2002-05-08 Draeger Medical Ag Arrangement and method for regulating a numerical value for patient ventilation
US6757558B2 (en) * 2000-07-06 2004-06-29 Algodyne, Ltd. Objective pain measurement system and method
DE60139128D1 (en) 2000-08-18 2009-08-13 Masimo Corp PULSE OXIMETER WITH TWO OPERATING MODES
JP4537703B2 (en) * 2001-06-13 2010-09-08 コンピュメディクス・リミテッド Device for monitoring consciousness
US6850787B2 (en) 2001-06-29 2005-02-01 Masimo Laboratories, Inc. Signal component processor
US6697658B2 (en) 2001-07-02 2004-02-24 Masimo Corporation Low power pulse oximeter
US7355512B1 (en) 2002-01-24 2008-04-08 Masimo Corporation Parallel alarm processor
US6850788B2 (en) 2002-03-25 2005-02-01 Masimo Corporation Physiological measurement communications adapter
US7373198B2 (en) * 2002-07-12 2008-05-13 Bionova Technologies Inc. Method and apparatus for the estimation of anesthetic depth using wavelet analysis of the electroencephalogram
CA2704183A1 (en) * 2002-10-03 2004-04-15 Scott Laboratories, Inc. Neural networks in sedation and analgesia systems
US6970792B1 (en) 2002-12-04 2005-11-29 Masimo Laboratories, Inc. Systems and methods for determining blood oxygen saturation values using complex number encoding
US7189204B2 (en) 2002-12-04 2007-03-13 Cardiac Pacemakers, Inc. Sleep detection using an adjustable threshold
US7919713B2 (en) 2007-04-16 2011-04-05 Masimo Corporation Low noise oximetry cable including conductive cords
US6920345B2 (en) 2003-01-24 2005-07-19 Masimo Corporation Optical sensor including disposable and reusable elements
US7003338B2 (en) 2003-07-08 2006-02-21 Masimo Corporation Method and apparatus for reducing coupling between signals
US7500950B2 (en) 2003-07-25 2009-03-10 Masimo Corporation Multipurpose sensor port
US7668591B2 (en) 2003-09-18 2010-02-23 Cardiac Pacemakers, Inc. Automatic activation of medical processes
US8606356B2 (en) 2003-09-18 2013-12-10 Cardiac Pacemakers, Inc. Autonomic arousal detection system and method
US7787946B2 (en) 2003-08-18 2010-08-31 Cardiac Pacemakers, Inc. Patient monitoring, diagnosis, and/or therapy systems and methods
US7887493B2 (en) 2003-09-18 2011-02-15 Cardiac Pacemakers, Inc. Implantable device employing movement sensing for detecting sleep-related disorders
US8002553B2 (en) 2003-08-18 2011-08-23 Cardiac Pacemakers, Inc. Sleep quality data collection and evaluation
US7483729B2 (en) 2003-11-05 2009-01-27 Masimo Corporation Pulse oximeter access apparatus and method
US20050124866A1 (en) * 2003-11-12 2005-06-09 Joseph Elaz Healthcare processing device and display system
US7438683B2 (en) 2004-03-04 2008-10-21 Masimo Corporation Application identification sensor
JP2007527776A (en) 2004-03-08 2007-10-04 マシモ・コーポレイション Physiological parameter system
CA2464029A1 (en) 2004-04-08 2005-10-08 Valery Telfort Non-invasive ventilation monitor
US7447541B2 (en) * 2004-06-30 2008-11-04 Instrumentarium Corporation Monitoring subcortical responsiveness of a patient
US7343186B2 (en) 2004-07-07 2008-03-11 Masimo Laboratories, Inc. Multi-wavelength physiological monitor
US9341565B2 (en) 2004-07-07 2016-05-17 Masimo Corporation Multiple-wavelength physiological monitor
US7937128B2 (en) 2004-07-09 2011-05-03 Masimo Corporation Cyanotic infant sensor
US7254429B2 (en) 2004-08-11 2007-08-07 Glucolight Corporation Method and apparatus for monitoring glucose levels in a biological tissue
US8036727B2 (en) 2004-08-11 2011-10-11 Glt Acquisition Corp. Methods for noninvasively measuring analyte levels in a subject
US20060058700A1 (en) * 2004-08-26 2006-03-16 Marro Dominic P Patient sedation monitor
EP1860993B1 (en) 2005-03-01 2019-01-23 Masimo Laboratories, Inc. Noninvasive multi-parameter patient monitor
EP1874178A4 (en) 2005-04-13 2009-12-09 Glucolight Corp Method for data reduction and calibration of an oct-based blood glucose monitor
US7805187B2 (en) * 2005-07-07 2010-09-28 The General Electric Company Monitoring of the cerebral state of a subject
KR100719068B1 (en) * 2005-09-14 2007-05-17 재단법인 한국정신과학연구소 Apparatus and method of diagnosing health using cumulative data pattern analysis via fast Fourier transformation of brain wave data measured from frontal lobe
US7962188B2 (en) 2005-10-14 2011-06-14 Masimo Corporation Robust alarm system
EP2374407B1 (en) 2005-11-29 2021-05-05 Masimo Corporation Optical sensor including disposable and reusable elements
US8182443B1 (en) 2006-01-17 2012-05-22 Masimo Corporation Drug administration controller
US8219172B2 (en) 2006-03-17 2012-07-10 Glt Acquisition Corp. System and method for creating a stable optical interface
US7941199B2 (en) 2006-05-15 2011-05-10 Masimo Laboratories, Inc. Sepsis monitor
US9176141B2 (en) 2006-05-15 2015-11-03 Cercacor Laboratories, Inc. Physiological monitor calibration system
US8998809B2 (en) 2006-05-15 2015-04-07 Cercacor Laboratories, Inc. Systems and methods for calibrating minimally invasive and non-invasive physiological sensor devices
US8028701B2 (en) 2006-05-31 2011-10-04 Masimo Corporation Respiratory monitoring
US10188348B2 (en) 2006-06-05 2019-01-29 Masimo Corporation Parameter upgrade system
FR2903314B1 (en) * 2006-07-10 2018-01-12 Universite Pierre Et Marie Curie DEVICE FOR DETECTING INAPPROPRIATE ADJUSTMENT OF A VENTILATORY ASSISTANCE MACHINE USED ON A MAMMAL.
US8457707B2 (en) 2006-09-20 2013-06-04 Masimo Corporation Congenital heart disease monitor
US9161696B2 (en) 2006-09-22 2015-10-20 Masimo Corporation Modular patient monitor
US8840549B2 (en) 2006-09-22 2014-09-23 Masimo Corporation Modular patient monitor
ES2531254T3 (en) * 2006-09-29 2015-03-12 Univ California Outbreak suppression monitor for induced coma
US7880626B2 (en) 2006-10-12 2011-02-01 Masimo Corporation System and method for monitoring the life of a physiological sensor
US9861305B1 (en) 2006-10-12 2018-01-09 Masimo Corporation Method and apparatus for calibration to reduce coupling between signals in a measurement system
US8265723B1 (en) 2006-10-12 2012-09-11 Cercacor Laboratories, Inc. Oximeter probe off indicator defining probe off space
US8255026B1 (en) 2006-10-12 2012-08-28 Masimo Corporation, Inc. Patient monitor capable of monitoring the quality of attached probes and accessories
WO2008045538A2 (en) 2006-10-12 2008-04-17 Masimo Corporation Perfusion index smoother
US9192329B2 (en) 2006-10-12 2015-11-24 Masimo Corporation Variable mode pulse indicator
US8600467B2 (en) 2006-11-29 2013-12-03 Cercacor Laboratories, Inc. Optical sensor including disposable and reusable elements
EP2096994B1 (en) 2006-12-09 2018-10-03 Masimo Corporation Plethysmograph variability determination
US8852094B2 (en) 2006-12-22 2014-10-07 Masimo Corporation Physiological parameter system
US8652060B2 (en) 2007-01-20 2014-02-18 Masimo Corporation Perfusion trend indicator
US9402558B2 (en) * 2007-04-05 2016-08-02 New York University System and method for pain detection and computation of a pain quantification index
US8374665B2 (en) 2007-04-21 2013-02-12 Cercacor Laboratories, Inc. Tissue profile wellness monitor
US8764671B2 (en) 2007-06-28 2014-07-01 Masimo Corporation Disposable active pulse sensor
US8048040B2 (en) 2007-09-13 2011-11-01 Masimo Corporation Fluid titration system
US8310336B2 (en) 2008-10-10 2012-11-13 Masimo Corporation Systems and methods for storing, analyzing, retrieving and displaying streaming medical data
EP2227843B1 (en) 2007-10-12 2019-03-06 Masimo Corporation Connector assembly
WO2009079366A2 (en) * 2007-12-18 2009-06-25 New York University System and method for assessing efficacy of therapeutic agents
US8768423B2 (en) 2008-03-04 2014-07-01 Glt Acquisition Corp. Multispot monitoring for use in optical coherence tomography
JP5575752B2 (en) 2008-05-02 2014-08-20 マシモ コーポレイション Monitor configuration system
US9107625B2 (en) 2008-05-05 2015-08-18 Masimo Corporation Pulse oximetry system with electrical decoupling circuitry
US8577431B2 (en) 2008-07-03 2013-11-05 Cercacor Laboratories, Inc. Noise shielding for a noninvasive device
US20100030040A1 (en) 2008-08-04 2010-02-04 Masimo Laboratories, Inc. Multi-stream data collection system for noninvasive measurement of blood constituents
US8203438B2 (en) 2008-07-29 2012-06-19 Masimo Corporation Alarm suspend system
SE532941C2 (en) 2008-09-15 2010-05-18 Phasein Ab Gas sampling line for breathing gases
US8401602B2 (en) 2008-10-13 2013-03-19 Masimo Corporation Secondary-emitter sensor position indicator
US8346330B2 (en) 2008-10-13 2013-01-01 Masimo Corporation Reflection-detector sensor position indicator
US8771204B2 (en) 2008-12-30 2014-07-08 Masimo Corporation Acoustic sensor assembly
US8588880B2 (en) 2009-02-16 2013-11-19 Masimo Corporation Ear sensor
US10007758B2 (en) 2009-03-04 2018-06-26 Masimo Corporation Medical monitoring system
US10032002B2 (en) 2009-03-04 2018-07-24 Masimo Corporation Medical monitoring system
US9323894B2 (en) 2011-08-19 2016-04-26 Masimo Corporation Health care sanitation monitoring system
EP2404253B1 (en) 2009-03-04 2019-09-18 Masimo Corporation Medical monitoring system
US8388353B2 (en) 2009-03-11 2013-03-05 Cercacor Laboratories, Inc. Magnetic connector
US8155736B2 (en) * 2009-03-16 2012-04-10 Neurosky, Inc. EEG control of devices using sensory evoked potentials
US8391966B2 (en) * 2009-03-16 2013-03-05 Neurosky, Inc. Sensory-evoked potential (SEP) classification/detection in the time domain
US20100256515A1 (en) * 2009-04-03 2010-10-07 Egeth Marc J Communication with and consciousness-assessment of anesthetized surgery patients
US8914102B1 (en) 2009-04-20 2014-12-16 University Of South Florida Method and device for anesthesiology measurement and control
WO2010135373A1 (en) 2009-05-19 2010-11-25 Masimo Corporation Disposable components for reusable physiological sensor
US8571619B2 (en) 2009-05-20 2013-10-29 Masimo Corporation Hemoglobin display and patient treatment
US8471713B2 (en) 2009-07-24 2013-06-25 Cercacor Laboratories, Inc. Interference detector for patient monitor
US8473020B2 (en) 2009-07-29 2013-06-25 Cercacor Laboratories, Inc. Non-invasive physiological sensor cover
US8688183B2 (en) 2009-09-03 2014-04-01 Ceracor Laboratories, Inc. Emitter driver for noninvasive patient monitor
US20110172498A1 (en) 2009-09-14 2011-07-14 Olsen Gregory A Spot check monitor credit system
US9579039B2 (en) 2011-01-10 2017-02-28 Masimo Corporation Non-invasive intravascular volume index monitor
US20110137297A1 (en) 2009-09-17 2011-06-09 Kiani Massi Joe E Pharmacological management system
US8571618B1 (en) 2009-09-28 2013-10-29 Cercacor Laboratories, Inc. Adaptive calibration system for spectrophotometric measurements
US20110082711A1 (en) 2009-10-06 2011-04-07 Masimo Laboratories, Inc. Personal digital assistant or organizer for monitoring glucose levels
WO2011047216A2 (en) 2009-10-15 2011-04-21 Masimo Corporation Physiological acoustic monitoring system
US8755535B2 (en) 2009-10-15 2014-06-17 Masimo Corporation Acoustic respiratory monitoring sensor having multiple sensing elements
US8790268B2 (en) 2009-10-15 2014-07-29 Masimo Corporation Bidirectional physiological information display
US8430817B1 (en) 2009-10-15 2013-04-30 Masimo Corporation System for determining confidence in respiratory rate measurements
US10463340B2 (en) 2009-10-15 2019-11-05 Masimo Corporation Acoustic respiratory monitoring systems and methods
US9848800B1 (en) 2009-10-16 2017-12-26 Masimo Corporation Respiratory pause detector
US9839381B1 (en) 2009-11-24 2017-12-12 Cercacor Laboratories, Inc. Physiological measurement system with automatic wavelength adjustment
GB2487882B (en) 2009-12-04 2017-03-29 Masimo Corp Calibration for multi-stage physiological monitors
US9153112B1 (en) 2009-12-21 2015-10-06 Masimo Corporation Modular patient monitor
WO2011091059A1 (en) 2010-01-19 2011-07-28 Masimo Corporation Wellness analysis system
WO2011109312A2 (en) 2010-03-01 2011-09-09 Masimo Corporation Adaptive alarm system
US8584345B2 (en) 2010-03-08 2013-11-19 Masimo Corporation Reprocessing of a physiological sensor
US8700141B2 (en) * 2010-03-10 2014-04-15 Brainscope Company, Inc. Method and apparatus for automatic evoked potentials assessment
US9307928B1 (en) 2010-03-30 2016-04-12 Masimo Corporation Plethysmographic respiration processor
US8712494B1 (en) 2010-05-03 2014-04-29 Masimo Corporation Reflective non-invasive sensor
US9138180B1 (en) 2010-05-03 2015-09-22 Masimo Corporation Sensor adapter cable
US8666468B1 (en) 2010-05-06 2014-03-04 Masimo Corporation Patient monitor for determining microcirculation state
US20110295142A1 (en) * 2010-05-25 2011-12-01 Neurowave Systems Inc. Detector for identifying physiological artifacts from physiological signals and method
US9326712B1 (en) 2010-06-02 2016-05-03 Masimo Corporation Opticoustic sensor
US8740792B1 (en) 2010-07-12 2014-06-03 Masimo Corporation Patient monitor capable of accounting for environmental conditions
US9408542B1 (en) 2010-07-22 2016-08-09 Masimo Corporation Non-invasive blood pressure measurement system
US9649054B2 (en) 2010-08-26 2017-05-16 Cercacor Laboratories, Inc. Blood pressure measurement method
US9211095B1 (en) 2010-10-13 2015-12-15 Masimo Corporation Physiological measurement logic engine
US8723677B1 (en) 2010-10-20 2014-05-13 Masimo Corporation Patient safety system with automatically adjusting bed
US20120226117A1 (en) 2010-12-01 2012-09-06 Lamego Marcelo M Handheld processing device including medical applications for minimally and non invasive glucose measurements
WO2012109671A1 (en) 2011-02-13 2012-08-16 Masimo Corporation Medical characterization system
US9066666B2 (en) 2011-02-25 2015-06-30 Cercacor Laboratories, Inc. Patient monitor for monitoring microcirculation
US8830449B1 (en) 2011-04-18 2014-09-09 Cercacor Laboratories, Inc. Blood analysis system
US9095316B2 (en) 2011-04-20 2015-08-04 Masimo Corporation System for generating alarms based on alarm patterns
US9622692B2 (en) 2011-05-16 2017-04-18 Masimo Corporation Personal health device
US9532722B2 (en) 2011-06-21 2017-01-03 Masimo Corporation Patient monitoring system
US9986919B2 (en) 2011-06-21 2018-06-05 Masimo Corporation Patient monitoring system
US9245668B1 (en) 2011-06-29 2016-01-26 Cercacor Laboratories, Inc. Low noise cable providing communication between electronic sensor components and patient monitor
US11439329B2 (en) 2011-07-13 2022-09-13 Masimo Corporation Multiple measurement mode in a physiological sensor
US9192351B1 (en) 2011-07-22 2015-11-24 Masimo Corporation Acoustic respiratory monitoring sensor with probe-off detection
US8755872B1 (en) 2011-07-28 2014-06-17 Masimo Corporation Patient monitoring system for indicating an abnormal condition
US9782077B2 (en) 2011-08-17 2017-10-10 Masimo Corporation Modulated physiological sensor
EP3584799B1 (en) 2011-10-13 2022-11-09 Masimo Corporation Medical monitoring hub
US9943269B2 (en) 2011-10-13 2018-04-17 Masimo Corporation System for displaying medical monitoring data
EP3603502B1 (en) 2011-10-13 2023-10-04 Masimo Corporation Physiological acoustic monitoring system
US9808188B1 (en) 2011-10-13 2017-11-07 Masimo Corporation Robust fractional saturation determination
US9778079B1 (en) 2011-10-27 2017-10-03 Masimo Corporation Physiological monitor gauge panel
US9445759B1 (en) 2011-12-22 2016-09-20 Cercacor Laboratories, Inc. Blood glucose calibration system
US11172890B2 (en) 2012-01-04 2021-11-16 Masimo Corporation Automated condition screening and detection
US9392945B2 (en) 2012-01-04 2016-07-19 Masimo Corporation Automated CCHD screening and detection
US10149616B2 (en) 2012-02-09 2018-12-11 Masimo Corporation Wireless patient monitoring device
US9480435B2 (en) 2012-02-09 2016-11-01 Masimo Corporation Configurable patient monitoring system
US10307111B2 (en) 2012-02-09 2019-06-04 Masimo Corporation Patient position detection system
WO2013148605A1 (en) 2012-03-25 2013-10-03 Masimo Corporation Physiological monitor touchscreen interface
EP2838428B1 (en) 2012-04-17 2023-09-06 Masimo Corporation Hypersaturation index
US10542903B2 (en) 2012-06-07 2020-01-28 Masimo Corporation Depth of consciousness monitor
US9697928B2 (en) 2012-08-01 2017-07-04 Masimo Corporation Automated assembly sensor cable
US10827961B1 (en) 2012-08-29 2020-11-10 Masimo Corporation Physiological measurement calibration
US9955937B2 (en) 2012-09-20 2018-05-01 Masimo Corporation Acoustic patient sensor coupler
US9749232B2 (en) 2012-09-20 2017-08-29 Masimo Corporation Intelligent medical network edge router
US9877650B2 (en) 2012-09-20 2018-01-30 Masimo Corporation Physiological monitor with mobile computing device connectivity
US9717458B2 (en) 2012-10-20 2017-08-01 Masimo Corporation Magnetic-flap optical sensor
US9560996B2 (en) 2012-10-30 2017-02-07 Masimo Corporation Universal medical system
US9787568B2 (en) 2012-11-05 2017-10-10 Cercacor Laboratories, Inc. Physiological test credit method
US9750461B1 (en) 2013-01-02 2017-09-05 Masimo Corporation Acoustic respiratory monitoring sensor with probe-off detection
US9724025B1 (en) 2013-01-16 2017-08-08 Masimo Corporation Active-pulse blood analysis system
US9750442B2 (en) 2013-03-09 2017-09-05 Masimo Corporation Physiological status monitor
US10441181B1 (en) 2013-03-13 2019-10-15 Masimo Corporation Acoustic pulse and respiration monitoring system
WO2014164139A1 (en) 2013-03-13 2014-10-09 Masimo Corporation Systems and methods for monitoring a patient health network
US9474474B2 (en) 2013-03-14 2016-10-25 Masimo Corporation Patient monitor as a minimally invasive glucometer
US9986952B2 (en) 2013-03-14 2018-06-05 Masimo Corporation Heart sound simulator
US9936917B2 (en) 2013-03-14 2018-04-10 Masimo Laboratories, Inc. Patient monitor placement indicator
US10456038B2 (en) 2013-03-15 2019-10-29 Cercacor Laboratories, Inc. Cloud-based physiological monitoring system
US20160029965A1 (en) * 2013-03-15 2016-02-04 Adam J. Simon Artifact as a feature in neuro diagnostics
US9891079B2 (en) 2013-07-17 2018-02-13 Masimo Corporation Pulser with double-bearing position encoder for non-invasive physiological monitoring
WO2015020911A2 (en) 2013-08-05 2015-02-12 Cercacor Laboratories, Inc. Blood pressure monitor with valve-chamber assembly
WO2015038683A2 (en) 2013-09-12 2015-03-19 Cercacor Laboratories, Inc. Medical device management system
EP3054849B1 (en) 2013-10-07 2022-03-16 Masimo Corporation Regional oximetry sensor
US11147518B1 (en) 2013-10-07 2021-10-19 Masimo Corporation Regional oximetry signal processor
US10832818B2 (en) 2013-10-11 2020-11-10 Masimo Corporation Alarm notification system
US10828007B1 (en) 2013-10-11 2020-11-10 Masimo Corporation Acoustic sensor with attachment portion
US10279247B2 (en) 2013-12-13 2019-05-07 Masimo Corporation Avatar-incentive healthcare therapy
US11259745B2 (en) 2014-01-28 2022-03-01 Masimo Corporation Autonomous drug delivery system
US10086138B1 (en) 2014-01-28 2018-10-02 Masimo Corporation Autonomous drug delivery system
US10532174B2 (en) 2014-02-21 2020-01-14 Masimo Corporation Assistive capnography device
US9924897B1 (en) 2014-06-12 2018-03-27 Masimo Corporation Heated reprocessing of physiological sensors
US10123729B2 (en) 2014-06-13 2018-11-13 Nanthealth, Inc. Alarm fatigue management systems and methods
US10231670B2 (en) 2014-06-19 2019-03-19 Masimo Corporation Proximity sensor in pulse oximeter
US10111591B2 (en) 2014-08-26 2018-10-30 Nanthealth, Inc. Real-time monitoring systems and methods in a healthcare environment
US10231657B2 (en) 2014-09-04 2019-03-19 Masimo Corporation Total hemoglobin screening sensor
US10383520B2 (en) 2014-09-18 2019-08-20 Masimo Semiconductor, Inc. Enhanced visible near-infrared photodiode and non-invasive physiological sensor
US10441196B2 (en) 2015-01-23 2019-10-15 Masimo Corporation Nasal/oral cannula system and manufacturing
BR112017016308B1 (en) 2015-02-06 2023-04-11 Masimo Corporation CONNECTOR AND SENSOR ASSEMBLY
US10568553B2 (en) 2015-02-06 2020-02-25 Masimo Corporation Soft boot pulse oximetry sensor
USD755392S1 (en) 2015-02-06 2016-05-03 Masimo Corporation Pulse oximetry sensor
EP4329439A2 (en) 2015-02-06 2024-02-28 Masimo Corporation Fold flex circuit for lnop
US10524738B2 (en) 2015-05-04 2020-01-07 Cercacor Laboratories, Inc. Noninvasive sensor system with visual infographic display
WO2016191307A1 (en) 2015-05-22 2016-12-01 Cercacor Laboratories, Inc. Non-invasive optical physiological differential pathlength sensor
US10448871B2 (en) 2015-07-02 2019-10-22 Masimo Corporation Advanced pulse oximetry sensor
KR20180039703A (en) 2015-08-11 2018-04-18 마시모 코오퍼레이션 Medical monitoring analysis and replay including signs of reacting to light weakened by body tissues
CA2996196A1 (en) 2015-08-31 2017-03-09 Masimo Corporation Wireless patient monitoring systems and methods
US11504066B1 (en) 2015-09-04 2022-11-22 Cercacor Laboratories, Inc. Low-noise sensor system
US11679579B2 (en) 2015-12-17 2023-06-20 Masimo Corporation Varnish-coated release liner
US10806858B2 (en) 2016-02-17 2020-10-20 Zyno Medical, Llc Automatic anesthesiology pump allowing improved anesthesiologist mobility
US10993662B2 (en) 2016-03-04 2021-05-04 Masimo Corporation Nose sensor
US10537285B2 (en) 2016-03-04 2020-01-21 Masimo Corporation Nose sensor
US11191484B2 (en) 2016-04-29 2021-12-07 Masimo Corporation Optical sensor tape
WO2018009612A1 (en) 2016-07-06 2018-01-11 Patient Doctor Technologies, Inc. Secure and zero knowledge data sharing for cloud applications
US10617302B2 (en) 2016-07-07 2020-04-14 Masimo Corporation Wearable pulse oximeter and respiration monitor
CN106137187B (en) * 2016-07-15 2019-01-08 广州视源电子科技股份有限公司 A kind of brain electricity condition detection method and device
EP3525661A1 (en) 2016-10-13 2019-08-21 Masimo Corporation Systems and methods for patient fall detection
US11504058B1 (en) 2016-12-02 2022-11-22 Masimo Corporation Multi-site noninvasive measurement of a physiological parameter
WO2018119239A1 (en) 2016-12-22 2018-06-28 Cercacor Laboratories, Inc Methods and devices for detecting intensity of light with translucent detector
US10721785B2 (en) 2017-01-18 2020-07-21 Masimo Corporation Patient-worn wireless physiological sensor with pairing functionality
US11086609B2 (en) 2017-02-24 2021-08-10 Masimo Corporation Medical monitoring hub
WO2018156809A1 (en) 2017-02-24 2018-08-30 Masimo Corporation Augmented reality system for displaying patient data
US10388120B2 (en) 2017-02-24 2019-08-20 Masimo Corporation Localized projection of audible noises in medical settings
WO2018156648A1 (en) 2017-02-24 2018-08-30 Masimo Corporation Managing dynamic licenses for physiological parameters in a patient monitoring environment
US10327713B2 (en) 2017-02-24 2019-06-25 Masimo Corporation Modular multi-parameter patient monitoring device
US11417426B2 (en) 2017-02-24 2022-08-16 Masimo Corporation System for displaying medical monitoring data
WO2018165618A1 (en) 2017-03-10 2018-09-13 Masimo Corporation Pneumonia screener
WO2018182531A1 (en) * 2017-03-31 2018-10-04 Agency For Science, Technology And Research System and method for detecting eye activity
WO2018194992A1 (en) 2017-04-18 2018-10-25 Masimo Corporation Nose sensor
US10918281B2 (en) 2017-04-26 2021-02-16 Masimo Corporation Medical monitoring device having multiple configurations
USD835282S1 (en) 2017-04-28 2018-12-04 Masimo Corporation Medical monitoring device
USD835283S1 (en) 2017-04-28 2018-12-04 Masimo Corporation Medical monitoring device
US10856750B2 (en) 2017-04-28 2020-12-08 Masimo Corporation Spot check measurement system
USD835285S1 (en) 2017-04-28 2018-12-04 Masimo Corporation Medical monitoring device
USD835284S1 (en) 2017-04-28 2018-12-04 Masimo Corporation Medical monitoring device
CN117373636A (en) 2017-05-08 2024-01-09 梅西莫股份有限公司 System for pairing a medical system with a network controller using an adapter
US11026604B2 (en) 2017-07-13 2021-06-08 Cercacor Laboratories, Inc. Medical monitoring device for harmonizing physiological measurements
USD906970S1 (en) 2017-08-15 2021-01-05 Masimo Corporation Connector
EP3668394A1 (en) 2017-08-15 2020-06-24 Masimo Corporation Water resistant connector for noninvasive patient monitor
USD890708S1 (en) 2017-08-15 2020-07-21 Masimo Corporation Connector
US11298021B2 (en) 2017-10-19 2022-04-12 Masimo Corporation Medical monitoring system
USD925597S1 (en) 2017-10-31 2021-07-20 Masimo Corporation Display screen or portion thereof with graphical user interface
JP7282085B2 (en) 2017-10-31 2023-05-26 マシモ・コーポレイション System for displaying oxygen status indicators
US10456054B2 (en) 2017-11-02 2019-10-29 Bank Of America Corporation Electroencephalogram triggered resource distribution query system
US10567961B2 (en) 2017-11-02 2020-02-18 Bank Of America Corporation System for electroencephalogram patterning recognition for authentication
US11152086B2 (en) 2017-11-02 2021-10-19 Bank Of America Corporation Electroencephalogram triggered experience modification system
US11766198B2 (en) 2018-02-02 2023-09-26 Cercacor Laboratories, Inc. Limb-worn patient monitoring device
WO2019204368A1 (en) 2018-04-19 2019-10-24 Masimo Corporation Mobile patient alarm display
US11883129B2 (en) 2018-04-24 2024-01-30 Cercacor Laboratories, Inc. Easy insert finger sensor for transmission based spectroscopy sensor
US10932729B2 (en) 2018-06-06 2021-03-02 Masimo Corporation Opioid overdose monitoring
US10779098B2 (en) 2018-07-10 2020-09-15 Masimo Corporation Patient monitor alarm speaker analyzer
US11872156B2 (en) 2018-08-22 2024-01-16 Masimo Corporation Core body temperature measurement
US11406286B2 (en) 2018-10-11 2022-08-09 Masimo Corporation Patient monitoring device with improved user interface
USD998630S1 (en) 2018-10-11 2023-09-12 Masimo Corporation Display screen or portion thereof with a graphical user interface
MX2021004063A (en) 2018-10-11 2021-06-04 Masimo Corp Patient connector assembly with vertical detents.
USD999246S1 (en) 2018-10-11 2023-09-19 Masimo Corporation Display screen or portion thereof with a graphical user interface
USD916135S1 (en) 2018-10-11 2021-04-13 Masimo Corporation Display screen or portion thereof with a graphical user interface
USD917550S1 (en) 2018-10-11 2021-04-27 Masimo Corporation Display screen or portion thereof with a graphical user interface
USD998631S1 (en) 2018-10-11 2023-09-12 Masimo Corporation Display screen or portion thereof with a graphical user interface
US11389093B2 (en) 2018-10-11 2022-07-19 Masimo Corporation Low noise oximetry cable
USD917564S1 (en) 2018-10-11 2021-04-27 Masimo Corporation Display screen or portion thereof with graphical user interface
USD897098S1 (en) 2018-10-12 2020-09-29 Masimo Corporation Card holder set
WO2020077149A1 (en) 2018-10-12 2020-04-16 Masimo Corporation System for transmission of sensor data using dual communication protocol
US11464410B2 (en) 2018-10-12 2022-10-11 Masimo Corporation Medical systems and methods
US11684296B2 (en) 2018-12-21 2023-06-27 Cercacor Laboratories, Inc. Noninvasive physiological sensor
US20210022628A1 (en) 2019-04-17 2021-01-28 Masimo Corporation Patient monitoring systems, devices, and methods
USD921202S1 (en) 2019-08-16 2021-06-01 Masimo Corporation Holder for a blood pressure device
USD919094S1 (en) 2019-08-16 2021-05-11 Masimo Corporation Blood pressure device
USD917704S1 (en) 2019-08-16 2021-04-27 Masimo Corporation Patient monitor
USD985498S1 (en) 2019-08-16 2023-05-09 Masimo Corporation Connector
USD919100S1 (en) 2019-08-16 2021-05-11 Masimo Corporation Holder for a patient monitor
US11832940B2 (en) 2019-08-27 2023-12-05 Cercacor Laboratories, Inc. Non-invasive medical monitoring device for blood analyte measurements
CN114667574A (en) 2019-10-18 2022-06-24 梅西莫股份有限公司 Display layout and interactive objects for patient monitoring
USD927699S1 (en) 2019-10-18 2021-08-10 Masimo Corporation Electrode pad
EP4104037A1 (en) 2020-02-13 2022-12-21 Masimo Corporation System and method for monitoring clinical activities
US11879960B2 (en) 2020-02-13 2024-01-23 Masimo Corporation System and method for monitoring clinical activities
EP4120901A1 (en) 2020-03-20 2023-01-25 Masimo Corporation Wearable device for noninvasive body temperature measurement
USD933232S1 (en) 2020-05-11 2021-10-12 Masimo Corporation Blood pressure monitor
USD979516S1 (en) 2020-05-11 2023-02-28 Masimo Corporation Connector
KR20210146723A (en) * 2020-05-27 2021-12-06 주식회사 브레인유 Consciousness Level Determination Method and Computer Program
USD974193S1 (en) 2020-07-27 2023-01-03 Masimo Corporation Wearable temperature measurement device
USD980091S1 (en) 2020-07-27 2023-03-07 Masimo Corporation Wearable temperature measurement device
USD946596S1 (en) 2020-09-30 2022-03-22 Masimo Corporation Display screen or portion thereof with graphical user interface
USD946597S1 (en) 2020-09-30 2022-03-22 Masimo Corporation Display screen or portion thereof with graphical user interface
USD946598S1 (en) 2020-09-30 2022-03-22 Masimo Corporation Display screen or portion thereof with graphical user interface
USD997365S1 (en) 2021-06-24 2023-08-29 Masimo Corporation Physiological nose sensor
USD1000975S1 (en) 2021-09-22 2023-10-10 Masimo Corporation Wearable temperature measurement device

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6067467A (en) * 1994-02-07 2000-05-23 New York University EEG operative and post-operative patient monitoring method
US5813993A (en) * 1996-04-05 1998-09-29 Consolidated Research Of Richmond, Inc. Alertness and drowsiness detection and tracking system
US6230049B1 (en) * 1999-08-13 2001-05-08 Neuro Pace, Inc. Integrated system for EEG monitoring and electrical stimulation with a multiplicity of electrodes

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090143694A1 (en) * 2000-12-07 2009-06-04 Baruch Shlomo Krauss Automated interpretive medical care system and methodology
US20040236240A1 (en) * 2000-12-07 2004-11-25 Kraus Baruch Shlomo Automated interpretive medical care system and methodology
US10610110B2 (en) 2000-12-07 2020-04-07 Children's Medical Center Corporation Automated interpretive medical care system and methodology
US9993163B2 (en) 2000-12-07 2018-06-12 Oridion Medical 1987 Ltd. Automated interpretive medical care system and methodology
US9955875B2 (en) 2000-12-07 2018-05-01 Oridion Medical 1987 Ltd. Automated interpretive medical care system and methodology
US9895065B2 (en) 2000-12-07 2018-02-20 Children's Medical Center Corporation Automated interpretive medical care system and methodology
US9895066B2 (en) 2000-12-07 2018-02-20 Oridion Medical 1987 Ltd. Automated interpretive medical care system and methodology
US8679029B2 (en) * 2000-12-07 2014-03-25 Oridion Medical (1987) Ltd. Automated interpretive medical care system and methodology
US8147419B2 (en) 2000-12-07 2012-04-03 Baruch Shlomo Krauss Automated interpretive medical care system and methodology
US20090149723A1 (en) * 2000-12-07 2009-06-11 Baruch Shlomo Krauss Automated interpretive medical care system and methodology
US7654948B2 (en) 2003-02-28 2010-02-02 Consolidate Research of Richmond, Inc. Automated insomnia treatment system
US20040225179A1 (en) * 2003-02-28 2004-11-11 Consolidated Research Of Richmond, Inc. Automated insomnia treatment system
US8512221B2 (en) 2003-02-28 2013-08-20 Consolidated Research Of Richmond, Inc. Automated treatment system for sleep
US20100094103A1 (en) * 2003-02-28 2010-04-15 Consolidated Research Of Richmond, Inc Automated treatment system for sleep
US20040243017A1 (en) * 2003-05-06 2004-12-02 Elvir Causevic Anesthesia and sedation monitoring system and method
US20060019224A1 (en) * 2004-07-23 2006-01-26 Pics, Inc. Insomnia assessment and treatment device and method
US8073534B2 (en) * 2005-05-10 2011-12-06 Philip Low Automated detection of sleep and waking states
US20070016095A1 (en) * 2005-05-10 2007-01-18 Low Philip S Automated detection of sleep and waking states
US11690557B2 (en) * 2005-05-10 2023-07-04 The Salk Institute For Biological Studies Intellectual Property And Technology Transfer Automated detection of sleep and waking states
JP2008544772A (en) * 2005-05-10 2008-12-11 ザ サルク インスティテュート フォー バイオロジカル スタディーズ Automatic detection of sleep and wakefulness
JP2014176743A (en) * 2005-05-10 2014-09-25 Salk Institute For Biological Studies:The Sleep-awake state automatic detection
US20120029378A1 (en) * 2005-05-10 2012-02-02 Salk Institute For Biological Studies, The Intellectual Property And Technology Transfer Automated detection of sleep and waking states
US7428290B2 (en) 2005-09-27 2008-09-23 Ge Medical Systems Global Technology Company, Llc X-ray CT apparatus
US20070071160A1 (en) * 2005-09-27 2007-03-29 Akihiko Nishide X-ray ct apparatus
WO2007059248A2 (en) * 2005-11-15 2007-05-24 Hospira, Inc System for monitoring and separating eeg and emg signals
WO2007059248A3 (en) * 2005-11-15 2009-04-30 Hospira Inc System for monitoring and separating eeg and emg signals
US20070167694A1 (en) * 2005-12-21 2007-07-19 Everest Biomedical Instruments Co. Integrated Portable Anesthesia and Sedation Monitoring Apparatus
US20140228651A1 (en) * 2005-12-21 2014-08-14 Brainscope Company, Inc. Integrated portable anesthesia and sedation monitoring apparatus
US20070185697A1 (en) * 2006-02-07 2007-08-09 Microsoft Corporation Using electroencephalograph signals for task classification and activity recognition
US7580742B2 (en) * 2006-02-07 2009-08-25 Microsoft Corporation Using electroencephalograph signals for task classification and activity recognition
US20080317672A1 (en) * 2007-06-20 2008-12-25 The General Electric Company Detection of anomalies in measurement of level of hypnosis
US9398863B2 (en) * 2007-06-20 2016-07-26 General Electric Company Detection of anomalies in measurement of level of hypnosis
US8838198B2 (en) 2008-11-14 2014-09-16 Neuronetrix Solutions, Llc Electrode system
US8864702B2 (en) * 2009-01-15 2014-10-21 Hopital Foch System for controlling means for injection of anesthetics or sedatives
US10537677B2 (en) 2009-01-15 2020-01-21 Medsteer System for controlling injectors of anaesthetics or sedatives with a view to inducing anaesthesia or sedation
US20110295196A1 (en) * 2009-01-15 2011-12-01 Hopital Foch System for controlling means for injection of anesthetics or sedatives
DE102009053256A1 (en) * 2009-11-06 2011-05-19 Baars, Jan H., Dr. med. Method for determining the analgesic level of a sedated or anaesthetized individual
US8364255B2 (en) * 2010-03-10 2013-01-29 Brainscope Company, Inc. Method and device for removing EEG artifacts
US20110224569A1 (en) * 2010-03-10 2011-09-15 Robert Isenhart Method and device for removing eeg artifacts
US11717210B2 (en) 2010-09-28 2023-08-08 Masimo Corporation Depth of consciousness monitor including oximeter
US8821397B2 (en) 2010-09-28 2014-09-02 Masimo Corporation Depth of consciousness monitor including oximeter
US9775545B2 (en) 2010-09-28 2017-10-03 Masimo Corporation Magnetic electrical connector for patient monitors
US9538949B2 (en) 2010-09-28 2017-01-10 Masimo Corporation Depth of consciousness monitor including oximeter
US10531811B2 (en) 2010-09-28 2020-01-14 Masimo Corporation Depth of consciousness monitor including oximeter
US20140081094A1 (en) * 2011-05-02 2014-03-20 Denis Jordan Method for consciousness and pain monitoring, module for analyzing eeg signals, and eeg anesthesia monitor
US8666484B2 (en) 2011-11-25 2014-03-04 Persyst Development Corporation Method and system for displaying EEG data
US9820663B2 (en) 2012-01-24 2017-11-21 Neurovigil, Inc. Correlating brain signal to intentional and unintentional changes in brain state
US9364163B2 (en) 2012-01-24 2016-06-14 Neurovigil, Inc. Correlating brain signal to intentional and unintentional changes in brain state
CN103040459A (en) * 2013-01-05 2013-04-17 西安交通大学 Method of high-fidelity filtering for power frequency interferences in multichannel feeble physiological information recording system
CN103169466A (en) * 2013-04-01 2013-06-26 张宇奇 Algesia monitoring system and monitoring method for anesthesia
US9849241B2 (en) 2013-04-24 2017-12-26 Fresenius Kabi Deutschland Gmbh Method of operating a control device for controlling an infusion device
US10765367B2 (en) 2014-10-07 2020-09-08 Masimo Corporation Modular physiological sensors
US10154815B2 (en) 2014-10-07 2018-12-18 Masimo Corporation Modular physiological sensors
US11717218B2 (en) 2014-10-07 2023-08-08 Masimo Corporation Modular physiological sensor
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11273283B2 (en) 2017-12-31 2022-03-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11318277B2 (en) 2017-12-31 2022-05-03 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US11452839B2 (en) 2018-09-14 2022-09-27 Neuroenhancement Lab, LLC System and method of improving sleep
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep

Also Published As

Publication number Publication date
US6317627B1 (en) 2001-11-13

Similar Documents

Publication Publication Date Title
US6317627B1 (en) Anesthesia monitoring system based on electroencephalographic signals
US6067467A (en) EEG operative and post-operative patient monitoring method
US11553869B1 (en) Multi-channel brain or cortical activity monitoring and method
US5699808A (en) EEG operative and post-operative patient monitoring system and method
Kane et al. A revised glossary of terms most commonly used by clinical electroencephalographers and updated proposal for the report format of the EEG findings. Revision 2017
US7711417B2 (en) System and method for guidance of anesthesia, analgesia and amnesia
US6016444A (en) Automatic control of anesthesia using quantitative EEG
EP1989998B1 (en) Methods and apparatus for monitoring consciousness
EP1124611B1 (en) Alertness and drowsiness detection and tracking system
EP1665981A1 (en) Identification of a dominant signal component in a biosignal
EP1757226B1 (en) Measurement of responsiveness of a patient under anaesthesia
EP1854404B1 (en) Monitoring of the state of the central nervous system of a subject
EP1250886B1 (en) Anesthesia monitoring system based on electroencephalographic signals
Mccarron Psychophysiological discriminants of reactive depression
Tasker et al. The cerebral function analysing monitor in paediatric medical intensive care: applications and limitations
Joysly et al. Abnormality recognition during drowsy state from ECG and EEG
Lonishin EEG changes and C-Trend parameters in healthy patients during induction of anesthesia
Imhoff Correlation between the EEG monitors BIS and State entropy and their performance in differentiate consciousness and unconsciousness-an EEG Reanalysis
Miles et al. Graphical neurofeedback interface for the non-pharmacological intervention in attention deficit/attention deficit hyperactivity disorder
TR201918039A2 (en) Diagnosis and warning system
TWM451978U (en) Multi anesthesia depth signal measuring device

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE